AbbVie (ABBV) 10-Q 6 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 29, 2019
Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	001-35565
Entity Registrant Name	AbbVie Inc.
Entity Central Index Key	0001551152
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0375147
Entity Address, Address Line One	1 North Waukegan Road
Entity Address, City or Town	North Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064
City Area Code	847
Local Phone Number	932-7900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,478,821,109
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
Security Exchange Name	NYSE
Common Stock [Member] | CHICAGO STOCK EXCHANGE, INC [Member]
Entity Information
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
Security Exchange Name	CHX
Sec 1.375 Senior Notes Due 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information
Title of 12(b) Security	1.375% Senior Notes due 2024
Trading Symbol	ABBV24
Security Exchange Name	NYSE
Sec 0.750 Senior Notes Due 2027 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information
Title of 12(b) Security	0.750% Senior Notes due 2027
Trading Symbol	ABBV27
Security Exchange Name	NYSE
Sec 2.125 Senior Notes due 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information
Title of 12(b) Security	2.125% Senior Notes due 2028
Trading Symbol	ABBV28
Security Exchange Name	NYSE
Sec 1.250 Senior Notes due 2031 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information
Title of 12(b) Security	1.250% Senior Notes due 2031
Trading Symbol	ABBV31
Security Exchange Name	NYSE

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Net revenues	$ 8,479	$ 8,236	$ 24,562	$ 24,448
Cost of products sold	1,920	1,835	5,433	5,696
Selling, general and administrative	1,657	1,919	4,991	5,470
Research and development	2,285	1,268	4,865	3,834
Acquired in-process research and development	0	55	246	124
Other expense	0	0	0	500
Total operating costs and expenses	5,862	5,077	15,535	15,624
Operating earnings	2,617	3,159	9,027	8,824
Interest expense, net	420	302	1,054	825
Net foreign exchange loss	19	2	31	18
Other expense, net	177	94	2,590	411
Earnings before income tax expense	2,001	2,761	5,352	7,570
Income tax expense	117	14	271	57
Net earnings	$ 1,884	$ 2,747	$ 5,081	$ 7,513
Per share data
Basic earnings per share (in dollars per share)	$ 1.27	$ 1.81	$ 3.41	$ 4.81
Diluted earnings per share (in dollars per share)	$ 1.26	$ 1.81	$ 3.41	$ 4.79
Weighted-average basic shares outstanding (in shares)	1,481	1,511	1,480	1,556
Weighted-average diluted shares outstanding (in shares)	1,483	1,515	1,483	1,561

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net earnings	$ 1,884	$ 2,747	$ 5,081	$ 7,513
Foreign currency translation adjustments, net of tax expense (benefit) of $(16) for the three months and $(10) for the nine months ended September 30, 2019 and $3 for the three months and $(16) for the nine months ended September 30, 2018	(256)	30	(288)	(250)
Net investment hedging activities, net of tax expense (benefit) of $45 for the three months and $53 for the nine months ended September 30, 2019 and $(9) for the three months and $22 for the nine months ended September 30, 2018	156	(32)	184	73
Pension and post-employment benefits, net of tax expense (benefit) of $7 for the three months and $19 for the nine months ended September 30, 2019 and $8 for the three months and $24 for the nine months ended September 30, 2018	33	28	78	99
Marketable security activities, net of tax expense (benefit) of $— for the three months and $— for the nine months ended September 30, 2019 and $— for the three months and $— for the nine months ended September 30, 2018	(1)	0	10	(2)
Cash flow hedging activities, net of tax expense (benefit) of $18 for the three months and $9 for the nine months ended September 30, 2019 and $1 for the three months and $18 for the nine months ended September 30, 2018	31	54	(32)	248
Other comprehensive income (loss)	(37)	80	(48)	168
Comprehensive income	$ 1,847	$ 2,827	$ 5,033	$ 7,681

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Foreign currency translation adjustments, tax expense (benefit)	$ (16)	$ 3	$ (10)	$ (16)
Net investment hedging activities, tax expense (benefit)	45	(9)	53	22
Pension and post-employment benefits, tax expense (benefit)	7	8	19	24
Marketable security activities, tax expense (benefit)	0	0	0	0
Cash flow hedging activities, tax expense (benefit)	$ 18	$ 1	$ 9	$ 18

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Current assets
Cash and equivalents	$ 10,648	$ 7,289
Short-term investments	0	772
Accounts receivable, net	5,529	5,384
Inventories	1,929	1,605
Prepaid expenses and other	2,060	1,895
Total current assets	20,166	16,945
Investments	131	1,420
Property and equipment, net	2,894	2,883
Intangible assets, net	19,036	21,233
Goodwill	15,537	15,663
Other assets	1,677	1,208
Total assets	59,441	59,352
Current liabilities
Short-term borrowings	0	3,699
Current portion of long-term debt and finance lease obligations	5,276	1,609
Accounts payable and accrued liabilities	12,217	11,931
Total current liabilities	17,493	17,239
Long-term debt and finance lease obligations	33,126	35,002
Deferred income taxes	1,058	1,067
Other long-term liabilities	15,990	14,490
Commitments and contingencies
Stockholders’ equity (deficit)
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,781,429,626 shares issued as of September 30, 2019 and 1,776,510,871 as of December 31, 2018	18	18
Common stock held in treasury, at cost, 302,647,520 shares as of September 30, 2019 and 297,686,473 as of December 31, 2018	(24,501)	(24,108)
Additional paid-in capital	15,112	14,756
Retained earnings	3,673	3,368
Accumulated other comprehensive loss	(2,528)	(2,480)
Total stockholders’ equity (deficit)	(8,226)	(8,446)
Total liabilities and equity	$ 59,441	$ 59,352

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	4,000,000,000	4,000,000,000
Common stock, issued (in shares)	1,781,429,626	1,776,510,871
Common stock held in treasury, at cost (in shares)	302,647,520	297,686,473

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common stock	Treasury stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive loss
Beginning balance at Dec. 31, 2017	$ 5,097	$ 18	$ (11,923)	$ 14,270	$ 5,459	$ (2,727)
Beginning balance (in shares) at Dec. 31, 2017		1,592
Increase (Decrease) in Stockholders' Equity
Net earnings	7,513	$ 0	0	0	7,513	0
Other comprehensive income, net of tax	168	0	0	0	0	168
Dividends declared	(4,450)	0	0	0	(4,450)	0
Purchases of treasury stock	(9,956)	$ 0	(9,956)	0	0	0
Purchases of treasury stock (in shares)		(95)
Stock-based compensation plans and other	440	$ 0	30	410	0	0
Stock-based compensation plans and other (in shares)		7
Ending balance at Sep. 30, 2018	(2,921)	$ 18	(21,849)	14,680	6,789	(2,559)
Ending balance (in shares) at Sep. 30, 2018		1,504
Beginning balance at Jun. 30, 2018	(3,375)	$ 18	(20,845)	14,596	5,495	(2,639)
Beginning balance (in shares) at Jun. 30, 2018		1,514
Increase (Decrease) in Stockholders' Equity
Net earnings	2,747	$ 0	0	0	2,747	0
Other comprehensive income, net of tax	80	0	0	0	0	80
Dividends declared	(1,453)	0	0	0	(1,453)	0
Purchases of treasury stock	(1,009)	$ 0	(1,009)	0	0	0
Purchases of treasury stock (in shares)		(10)
Stock-based compensation plans and other	89	$ 0	5	84	0	0
Stock-based compensation plans and other (in shares)		0
Ending balance at Sep. 30, 2018	(2,921)	$ 18	(21,849)	14,680	6,789	(2,559)
Ending balance (in shares) at Sep. 30, 2018		1,504
Beginning balance at Dec. 31, 2018	(8,446)	$ 18	(24,108)	14,756	3,368	(2,480)
Beginning balance (in shares) at Dec. 31, 2018		1,479
Increase (Decrease) in Stockholders' Equity
Net earnings	5,081	$ 0	0	0	5,081	0
Other comprehensive income, net of tax	(48)	0	0	0	0	(48)
Dividends declared	(4,776)	0	0	0	(4,776)	0
Purchases of treasury stock	(425)	$ 0	(425)	0	0	0
Purchases of treasury stock (in shares)		(5)
Stock-based compensation plans and other	388	$ 0	32	356	0	0
Stock-based compensation plans and other (in shares)		5
Ending balance at Sep. 30, 2019	(8,226)	$ 18	(24,501)	15,112	3,673	(2,528)
Ending balance (in shares) at Sep. 30, 2019		1,479
Beginning balance at Jun. 30, 2019	(8,566)	$ 18	(24,505)	15,028	3,384	(2,491)
Beginning balance (in shares) at Jun. 30, 2019		1,478
Increase (Decrease) in Stockholders' Equity
Net earnings	1,884	$ 0	0	0	1,884	0
Other comprehensive income, net of tax	(37)	0	0	0	0	(37)
Dividends declared	(1,595)	0	0	0	(1,595)	0
Purchases of treasury stock	(3)	$ 0	(3)	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	91	$ 0	7	84	0	0
Stock-based compensation plans and other (in shares)		1
Ending balance at Sep. 30, 2019	$ (8,226)	$ 18	$ (24,501)	$ 15,112	$ 3,673	$ (2,528)
Ending balance (in shares) at Sep. 30, 2019		1,479

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net earnings	$ 5,081	$ 7,513
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	346	349
Amortization of intangible assets	1,162	974
Change in fair value of contingent consideration liabilities	2,653	432
Stock-based compensation	351	351
Upfront costs and milestones related to collaborations	341	711
Intangible asset impairment	1,030	0
Other, net	92	423
Changes in operating assets and liabilities:
Accounts receivable	(207)	(806)
Inventories	(401)	(367)
Prepaid expenses and other assets	183	(426)
Accounts payable and other liabilities	(582)	881
Cash flows from operating activities	10,049	10,035
Cash flows from investing activities
Acquisitions and investments	(476)	(541)
Acquisitions of property and equipment	(389)	(515)
Purchases of investment securities	(579)	(1,581)
Sales and maturities of investment securities	2,655	1,914
Cash flows from investing activities	1,211	(723)
Cash flows from financing activities
Net change in commercial paper borrowings	(699)	(400)
Proceeds from issuance of other short-term borrowings	0	3,002
Repayments of other short-term borrowings	(3,000)	0
Proceeds from issuance of long-term debt	1,534	5,963
Repayments of long-term debt and finance lease obligations	(5)	(5,021)
Debt issuance costs	(248)	(34)
Dividends paid	(4,771)	(4,129)
Purchases of treasury stock	(627)	(9,956)
Proceeds from the exercise of stock options	6	66
Payments of contingent consideration liabilities	(120)	(78)
Other, net	36	16
Cash flows from financing activities	(7,894)	(10,571)
Effect of exchange rate changes on cash and equivalents	(7)	(29)
Net change in cash and equivalents	3,359	(1,288)
Cash and equivalents, beginning of period	7,289	9,303
Cash and equivalents, end of period	$ 10,648	$ 8,015

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Basis of Historical Presentation The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2018 . It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. Certain reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU No. 2016-02 In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) . The standard outlined a comprehensive lease accounting model that superseded the previous lease guidance and required lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms greater than 12 months. The guidance also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. AbbVie adopted the standard in the first quarter of 2019 using the modified retrospective method. Results for reporting periods beginning after December 31, 2018 have been presented in accordance with the standard, while results for prior periods have not been adjusted and continue to be reported in accordance with AbbVie's historical accounting. The cumulative effect of initially applying the new leases standard was recognized as an adjustment to the opening condensed consolidated balance sheet as of January 1, 2019. The company elected a package of practical expedients for leases that commenced prior to January 1, 2019 and did not reassess historical conclusions on: (i) whether any expired or existing contracts are or contain leases; (ii) lease classification for any expired or existing leases; and (iii) initial direct costs capitalization for any existing leases. Under the new standard, on January 1, 2019, the company recognized a cumulative-effect adjustment to its condensed consolidated balance sheet primarily related to the recognition of liabilities and corresponding right-of-use assets for operating leases. The adjustment to the condensed consolidated balance sheet included: (i) a $405 million increase to other assets; (ii) a $115 million increase to accounts payable and accrued liabilities; and (iii) a $290 million increase to other long-term liabilities. Other cumulative-effect adjustments to the condensed consolidated balance sheet were insignificant. Adoption of the standard did not have a significant impact on AbbVie's condensed consolidated statements of earnings for the three and nine months ended September 30, 2019 . ASU No. 2018-02 In February 2018, the FASB issued ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allowed a reclassification from accumulated other comprehensive income (AOCI) to retained earnings for stranded tax effects related to adjustments to deferred taxes resulting from the December 2017 enactment of the Tax Cuts and Jobs Act (the Act). AbbVie adopted the standard in the first quarter of 2019. Upon adoption, the company made an election to not reclassify the income tax effects of the Act from AOCI to retained earnings. Therefore, the adoption of the standard had no impact on AbbVie's consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted ASU No. 2016-13 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) . The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. Additionally, the standard requires new disclosures and will be effective for AbbVie starting with the first quarter of 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact to retained earnings as of the beginning of the fiscal year of adoption. AbbVie is currently assessing the impact of adopting this guidance but does not expect a material impact on its consolidated financial statements based on the company’s current portfolio of financial assets.

Supplemental Financial Informat

Supplemental Financial Information	9 Months Ended
	Sep. 30, 2019
Supplemental Financial Information
Supplemental Financial Information	Supplemental Financial Information Interest Expense, Net Three months ended Nine months ended (in millions) 2019 2018 2019 2018 Interest expense $ 480 $ 339 $ 1,225 $ 968 Interest income (60 ) (37 ) (171 ) (143 ) Interest expense, net $ 420 $ 302 $ 1,054 $ 825 Inventories (in millions) September 30, 2019 December 31, 2018 Finished goods $ 449 $ 473 Work-in-process 1,120 862 Raw materials 360 270 Inventories $ 1,929 $ 1,605 Property and Equipment (in millions) September 30, 2019 December 31, 2018 Property and equipment, gross $ 8,492 $ 8,396 Accumulated depreciation (5,598 ) (5,513 ) Property and equipment, net $ 2,894 $ 2,883 Depreciation expense was $114 million for the three months and $346 million for the nine months ended September 30, 2019 and $115 million for the three months and $349 million for the nine months ended September 30, 2018 .

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive. The following table summarizes the impact of the two-class method: Three months ended Nine months ended (in millions, except per share data) 2019 2018 2019 2018 Basic EPS Net earnings $ 1,884 $ 2,747 $ 5,081 $ 7,513 Earnings allocated to participating securities 10 12 27 34 Earnings available to common shareholders $ 1,874 $ 2,735 $ 5,054 $ 7,479 Weighted-average basic shares outstanding 1,481 1,511 1,480 1,556 Basic earnings per share $ 1.27 $ 1.81 $ 3.41 $ 4.81 Diluted EPS Net earnings $ 1,884 $ 2,747 $ 5,081 $ 7,513 Earnings allocated to participating securities 10 12 27 34 Earnings available to common shareholders $ 1,874 $ 2,735 $ 5,054 $ 7,479 Weighted-average shares of common stock outstanding 1,481 1,511 1,480 1,556 Effect of dilutive securities 2 4 3 5 Weighted-average diluted shares outstanding 1,483 1,515 1,483 1,561 Diluted earnings per share $ 1.26 $ 1.81 $ 3.41 $ 4.79 Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

Licensing, Acquisitions, and Ot

Licensing, Acquisitions, and Other Arrangements	9 Months Ended
	Sep. 30, 2019
Licensing, Acquisitions, and Other Arrangements
Licensing, Acquisitions, and Other Arrangements	Licensing, Acquisitions and Other Arrangements Proposed Acquisition of Allergan plc On June 25, 2019, AbbVie announced that it entered into a definitive transaction agreement under which AbbVie will acquire Allergan plc (Allergan) in a cash and stock transaction for a transaction equity value of approximately $63 billion , based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019. Under the terms of the transaction agreement, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share. On October 14, 2019, Allergan shareholders approved the proposed transaction. In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a $38.0 billion 364 -day bridge credit agreement. On July 12, 2019, AbbVie entered into a term loan credit agreement with an aggregate principal amount of $6.0 billion consisting of a $1.5 billion 364 -day term loan tranche, a $2.5 billion three-year term loan tranche and a $2.0 billion five-year term loan tranche, with the commitments under the bridge credit agreement to be reduced by such amount to $32.0 billion . No amounts have been drawn under the bridge credit agreement or term loan credit agreement. On October 25, 2019, AbbVie commenced offers to exchange any and all outstanding notes of certain series issued by Allergan for up to $15.5 billion aggregate principal amount and €3.7 billion aggregate principal amount of new notes to be issued by AbbVie and cash, subject to conditions including the closing of the pending acquisition of Allergan. Concurrently with the offers to exchange the Allergan notes for AbbVie notes, the company solicited consents to adopt certain proposed amendments to each of the indentures governing the Allergan notes to, among other things, eliminate substantially all of the restrictive covenants in such indentures. Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of brands and products primarily focused on key therapeutic areas including medical aesthetics, eye care, neuroscience, gastroenterology and women's health. The transaction is expected to close in early 2020, subject to customary closing conditions and regulatory approvals. In September 2019, AbbVie and Allergan each received a Request for Additional Information (Second Request) from the Federal Trade Commission (FTC) in connection with the transaction. AbbVie and Allergan are cooperating fully with the FTC. Other Licensing & Acquisitions Activity Cash outflows related to other acquisitions and investments totaled $476 million for the nine months ended September 30, 2019 and $541 million for the nine months ended September 30, 2018 . AbbVie recorded no acquired in-process research and development (IPR&D) charges for the three months ended September 30, 2019 and recorded IPR&D charges of $246 million for the nine months ended September 30, 2019 . AbbVie recorded IPR&D charges of $55 million for the three months and $124 million for the nine months ended September 30, 2018 . Calico Life Sciences LLC In June 2018, AbbVie and Calico Life Sciences LLC (Calico) entered into an extension of a collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. Under the terms of the agreement, AbbVie and Calico will each contribute an additional $500 million to the collaboration and the term was extended for an additional three years . Calico will be responsible for research and early development until 2022 and will advance collaboration projects through Phase 2a through 2027. Following completion of Phase 2a, AbbVie will have the option to exclusively license collaboration compounds. AbbVie will support Calico in its early research and development efforts and, upon exercise, would be responsible for late-stage development and commercial activities. Collaboration costs and profits will be shared equally by both parties post option exercise. AbbVie recorded $500 million in other expense in the condensed consolidated statement of earnings related to its commitments under the agreement during the nine months ended September 30, 2018 . Reata Pharmaceuticals, Inc. In October 2019, AbbVie and Reata Pharmaceuticals, Inc. (Reata) entered into an amended and restated license agreement. Under the terms of the agreement, Reata reacquired exclusive development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie for territories outside of the United States with respect to bardoxolone methyl and worldwide with respect to omaveloxolone and other next-generation Nrf2 activators. As consideration for the rights reacquired by Reata, AbbVie will receive a total of $330 million in cash payable in three installments through 2021 which will be recognized in other income in future periods. In addition, AbbVie will receive low single-digit, tiered royalties from worldwide sales of omaveloxolone and certain next-generation Nrf2 activators.

Collaboration with Janssen Biot

Collaboration with Janssen Biotech, Inc.	9 Months Ended
	Sep. 30, 2019
Collaboration with Janssen Biotech, Inc.
Collaboration with Janssen Biotech, Inc.	Collaboration with Janssen Biotech, Inc. In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of IMBRUVICA, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase (BTK) and certain compounds structurally related to IMBRUVICA, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States. The collaboration provides Janssen with an exclusive license to commercialize IMBRUVICA outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs. In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of IMBRUVICA are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. Outside the United States, Janssen is responsible for and has exclusive rights to commercialize IMBRUVICA. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. The following table shows the profit and cost sharing relationship between Janssen and AbbVie: Three months ended Nine months ended (in millions) 2019 2018 2019 2018 United States - Janssen's share of profits (included in cost of products sold) $ 489 $ 377 $ 1,297 $ 978 International - AbbVie's share of profits (included in net revenues) 215 160 621 455 Global - AbbVie's share of other costs (included in respective line items) 81 81 230 232 AbbVie’s receivable from Janssen, included in accounts receivable, net, was $235 million at September 30, 2019 and $177 million at December 31, 2018 . AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $467 million at September 30, 2019 and $376 million at December 31, 2018 .

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2018 $ 15,663 Foreign currency translation adjustments (126 ) Balance as of September 30, 2019 $ 15,537 The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of September 30, 2019 , there were no accumulated goodwill impairment losses. Intangible Assets, Net The following table summarizes intangible assets: September 30, 2019 December 31, 2018 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 19,600 $ (6,208 ) $ 13,392 $ 15,872 $ (5,614 ) $ 10,258 License agreements 7,798 (2,154 ) 5,644 7,865 (1,810 ) 6,055 Total definite-lived intangible assets 27,398 (8,362 ) 19,036 23,737 (7,424 ) 16,313 Indefinite-lived research and development — — — 4,920 — 4,920 Total intangible assets, net $ 27,398 $ (8,362 ) $ 19,036 $ 28,657 $ (7,424 ) $ 21,233 Indefinite-Lived Intangible Assets Indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist. In the third quarter of 2019, following the announcement of the decision to terminate the rovalpituzumab tesirine (Rova-T) research and development program, the company recorded an impairment charge of $1.0 billion which represented the remaining value of the IPR&D acquired as part of the 2016 Stemcentrx acquisition . No indefinite-lived intangible asset impairment charges were recorded for the nine months ended September 30, 2018 . In April 2019, the U.S. Food and Drug Administration (FDA) and the European Commission approved SKYRIZI (risankizumab) for the treatment of moderate to severe plaque psoriasis. As a result, AbbVie reclassified $3.9 billion of indefinite-lived intangible assets related to SKYRIZI to developed product rights definite-lived intangible assets. This amount will be amortized over its estimated useful life using the estimated pattern of economic benefit. Definite-Lived Intangible Assets Amortization expense was $389 million for the three months and $1.2 billion for the nine months ended September 30, 2019 and $320 million for the three months and $974 million for the nine months ended September 30, 2018 . Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings. No definite-lived intangible asset impairment charges were recorded for the nine months ended September 30, 2019 and 2018 .

Restructuring Plans

Restructuring Plans	9 Months Ended
	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
Restructuring Plans	Restructuring Plans AbbVie recorded restructuring charges of $22 million for the three months and $208 million for the nine months ended September 30, 2019 and $22 million for the three months and $45 million for the nine months ended September 30, 2018 . Restructuring charges for the nine months ended September 30, 2019 primarily related to severance costs. The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2019 : (in millions) Accrued balance as of December 31, 2018 $ 99 Restructuring charges 194 Payments and other adjustments (133 ) Accrued balance as of September 30, 2019 $ 160

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	Leases AbbVie's lease portfolio primarily consists of real estate properties, vehicles and equipment. Short-term leases with a term of 12 months or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components. The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option. Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants. The following table summarizes the amounts and location of operating and finance leases on the condensed consolidated balance sheet: (in millions) Balance sheet caption September 30, Assets Operating Other assets $ 357 Finance Property and equipment, net 24 Total lease assets $ 381 Liabilities Operating Current Accounts payable and accrued liabilities $ 107 Noncurrent Other long-term liabilities 268 Finance Current Current portion of long-term debt and finance lease obligations 7 Noncurrent Long-term debt and finance lease obligations 21 Total lease liabilities $ 403 The following table summarizes the lease costs recognized in the condensed consolidated statements of earnings: Three months ended Nine months ended (in millions) 2019 2019 Operating lease cost $ 30 $ 94 Short-term lease cost 9 24 Variable lease cost 17 46 Total lease cost $ 56 $ 164 Sublease income and finance lease costs were insignificant for the three and nine months ended September 30, 2019 . The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases: September 30, Weighted-average remaining lease term (in years) Operating 6 Finance 3 Weighted-average discount rate Operating 4.0 % Finance 4.0 % The following table presents supplementary cash flow information regarding the company's leases: Nine months ended (in millions) 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 94 Right-of-use assets obtained in exchange for new operating lease liabilities 16 Finance lease cash flows were insignificant for the nine months ended September 30, 2019 . The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of September 30, 2019 : (in millions) Operating leases Finance leases Total (a)(b) 2019 $ 32 $ 6 $ 38 2020 116 10 126 2021 99 9 108 2022 56 3 59 2023 35 1 36 Thereafter 80 — 80 Total lease payments 418 29 447 Less: Interest 43 1 44 Present value of lease liabilities $ 375 $ 28 $ 403 (a) Total lease payments exclude approximately $350 million of contractual minimum lease payments for leases executed but not yet commenced. These leases will commence between years 2019 and 2020 with lease terms of approximately 11 years . (b) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.

Financial Instruments and Fair

Financial Instruments and Fair Value Measures	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measures	Financial Instruments and Fair Value Measures Risk Management Policy See Note 10 to the company's Annual Report on Form 10-K for the year ended December 31, 2018 for a summary of AbbVie's risk management policy and use of derivative instruments. Financial Instruments Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $0.2 billion at September 30, 2019 and $1.4 billion at December 31, 2018 , are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months . Accumulated gains and losses as of September 30, 2019 will be reclassified from AOCI and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement. In the third quarter of 2019, the company entered into treasury rate lock agreements to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the anticipated issuance of long-term debt in connection with the proposed acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and are recorded at fair value. Realized and unrealized gains or losses are included in AOCI and are expected to be reclassified to interest expense, net over the lives of the anticipated long-term debt issuances. These agreements had notional amounts totaling $10.0 billion at September 30, 2019 . The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $6.2 billion at September 30, 2019 and $8.6 billion at December 31, 2018 . The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had €3.6 billion aggregate principal amount of senior Euro notes designated as net investment hedges at September 30, 2019 and December 31, 2018 . In the third quarter of 2019, the company issued €1.4 billion aggregate principal amount of senior Euro notes and designated the principal amounts of this foreign denominated debt as net investment hedges. Concurrently, the company elected to de-designate hedge accounting for €1.4 billion aggregate principal amount of existing senior Euro notes. In addition, in the second quarter of 2019, the company entered into foreign currency forward exchange contracts with notional amounts totaling €971 million , £204 million and CHF62 million and designated the instruments as net investment hedges. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument. AbbVie is a party to interest rate hedge contracts designated as fair value hedges with notional amounts totaling $10.8 billion at September 30, 2019 and December 31, 2018 . The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges. The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets: Fair value – Fair value – (in millions) Balance sheet caption September 30, December 31, 2018 Balance sheet caption September 30, December 31, 2018 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 4 $ 113 Accounts payable and accrued liabilities $ — $ — Designated as net investment hedges Prepaid expenses and 69 — Accounts payable and accrued liabilities — — Not designated as hedges Prepaid expenses and other 13 19 Accounts payable and accrued liabilities 37 26 Treasury rate lock agreements designated as cash flow hedges Prepaid expenses and other 123 — Accounts payable and accrued liabilities 35 — Interest rate swaps designated as fair value hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 8 — Interest rate swaps designated as fair value hedges Other assets 44 — Other long-term liabilities 59 466 Total derivatives $ 253 $ 132 $ 139 $ 492 While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets. The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss): Three months ended Nine months ended (in millions) 2019 2018 2019 2018 Foreign currency forward exchange contracts Designated as cash flow hedges $ 3 $ 1 $ 8 $ 122 Designated as net investment hedges 59 — 69 — Treasury rate lock agreements designated as cash flow hedges 88 — 88 — Assuming market rates remain constant through contract maturities, the company expects to reclass pre-tax gains of $50 million into cost of products sold for foreign currency cash flow hedges and pre-tax gains of $3 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months. Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) pre-tax gains of $152 million for the three months and $187 million for the nine months ended September 30, 2019 and recognized a pre-tax loss of $41 million for the three months and a pre-tax gain of $95 million for the nine months ended September 30, 2018 . The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 11 for the amount of net gains (losses) reclassified out of AOCI. Three months ended Nine months ended (in millions) Statement of earnings caption 2019 2018 2019 2018 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ 42 $ (54 ) $ 119 $ (144 ) Designated as net investment hedges Interest expense, net 10 — 19 — Not designated as hedges Net foreign exchange loss (55 ) 22 (95 ) 91 Interest rate swaps designated as fair value hedges Interest expense, net 78 (63 ) 443 (306 ) Debt designated as hedged item in fair value hedges Interest expense, net (78 ) 63 (443 ) 306 Fair Value Measures The fair value hierarchy consists of the following three levels: • Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access; • Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and • Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability. The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of September 30, 2019 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant Assets Cash and equivalents $ 10,648 $ 1,288 $ 9,360 $ — Debt securities 2 — 2 — Equity securities 62 62 — — Interest rate hedges 44 — 44 — Foreign currency contracts 86 — 86 — Treasury rate lock agreements 123 — 123 — Total assets $ 10,965 $ 1,350 $ 9,615 $ — Liabilities Interest rate hedges $ 67 $ — $ 67 $ — Foreign currency contracts 37 — 37 — Treasury rate lock agreements 35 — 35 — Contingent consideration 6,957 — — 6,957 Total liabilities $ 7,096 $ — $ 139 $ 6,957 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2018 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant Assets Cash and equivalents $ 7,289 $ 1,209 $ 6,080 $ — Time deposits 568 — 568 — Debt securities 1,536 — 1,536 — Equity securities 4 4 — — Foreign currency contracts 132 — 132 — Total assets $ 9,529 $ 1,213 $ 8,316 $ — Liabilities Interest rate hedges $ 466 $ — $ 466 $ — Foreign currency contracts 26 — 26 — Contingent consideration 4,483 — — 4,483 Total liabilities $ 4,975 $ — $ 492 $ 4,483 The fair values of time deposits approximate their amortized cost due to the short maturities of these instruments. The fair values of available-for-sale debt securities were determined based on prices obtained from commercial pricing services. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. At September 30, 2019 , a 50 basis point increase/decrease in the assumed discount rate would have decreased/increased the value of the contingent consideration liabilities by approximately $270 million . Additionally, at September 30, 2019 , a five percentage point increase/decrease in the assumed probability of success across all potential indications still in development would have increased/decreased the value of the contingent consideration liabilities by approximately $140 million . There have been no transfers of assets or liabilities between the fair value measurement levels. The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs: Nine months ended (in millions) 2019 2018 Beginning balance $ 4,483 $ 4,534 Change in fair value recognized in net earnings 2,653 432 Payments (179 ) (100 ) Ending balance $ 6,957 $ 4,866 The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings. During the second quarter of 2019, the company recorded a $2.3 billion increase in the SKYRIZI contingent consideration liability due to higher probabilities of success, higher estimated future sales and declining interest rates. The higher probabilities of success resulted from the April 2019 regulatory approvals of SKYRIZI for the treatment of moderate to severe plaque psoriasis. During the third quarter of 2019, the company recorded a $91 million decrease in the Stemcentrx contingent consideration liability due to the termination of the Rova-T research and development program. Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of September 30, 2019 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant observable Significant Liabilities Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 5,284 $ 5,293 $ 5,286 $ 7 $ — Long-term debt and finance lease obligations, excluding fair value hedges 33,141 34,964 34,943 21 — Total liabilities $ 38,425 $ 40,257 $ 40,229 $ 28 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2018 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant observable Significant Liabilities Short-term borrowings $ 3,699 $ 3,693 $ — $ 3,693 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 1,609 1,617 1,609 8 — Long-term debt and finance lease obligations, excluding fair value hedges 35,468 34,052 34,024 28 — Total liabilities $ 40,776 $ 39,362 $ 35,633 $ 3,729 $ — AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $67 million as of September 30, 2019 and $84 million as of December 31, 2018 . No significant cumulative upward or downward adjustments have been recorded for these investments as of September 30, 2019 . Available-for-sale Securities Substantially all of the company’s investments in debt securities were classified as available-for-sale with changes in fair value recognized in other comprehensive income. There were no debt securities classified as short-term as of September 30, 2019 and there were $204 million as of December 31, 2018 . Estimated fair values of available-for-sale debt securities were generally determined based on prices obtained from commercial pricing services. In the third quarter of 2019, the company sold substantially all of its investments in debt securities. The following table summarizes available-for-sale securities by type as of December 31, 2018 : Amortized cost Gross unrealized Fair value (in millions) Gains Losses Asset backed securities $ 423 $ — $ (2 ) $ 421 Corporate debt securities 1,042 1 (9 ) 1,034 Other debt securities 81 — — 81 Total $ 1,546 $ 1 $ (11 ) $ 1,536 AbbVie had no other-than-temporary impairments as of September 30, 2019 . Net realized gains and losses were insignificant for both the three and nine months ended September 30, 2019 and 2018 . Concentrations of Risk Of total net accounts receivable, three U.S. wholesalers accounted for 68% as of September 30, 2019 and 63% as of December 31, 2018 , and substantially all of AbbVie’s net revenues in the United States were to these three wholesalers. HUMIRA (adalimumab) is AbbVie’s single largest product and accounted for approximately 58% of AbbVie’s total net revenues for the nine months ended September 30, 2019 and 61% for the nine months ended September 30, 2018 . Debt and Credit Facilities In September 2019, the company issued €1.4 billion aggregate principal amount of unsecured senior Euro notes, consisting of €750 million aggregate principal amount of 0.75% senior notes due 2027 and €650 million aggregate principal amount of 1.25% senior notes due 2031. These senior notes rank equally with all other unsecured and unsubordinated indebtedness of the company. AbbVie may redeem the senior notes prior to maturity at a redemption price equal to the principal amount of the senior notes redeemed plus a make-whole premium and may redeem the senior notes at par between one and three months prior to maturity. In connection with the offering, debt issuance costs incurred totaled $9 million and debt discounts totaled $5 million and are being amortized over the respective terms of the notes to interest expense, net in the condensed consolidated statements of earnings. In October 2019, the company used the proceeds to redeem €1.4 billion aggregate principal amount of 0.38% senior Euro notes that were due to mature in November 2019. Short-Term Borrowings Short-term borrowings included commercial paper borrowings of $699 million as of December 31, 2018 . There were no commercial paper borrowings outstanding as of September 30, 2019 . The weighted-average interest rate on commercial paper borrowings was 2.5% for the nine months ended September 30, 2019 and 1.9% for the nine months ended September 30, 2018 . In March 2019, AbbVie repaid its $3.0 billion 364 -day term loan credit agreement that was scheduled to mature in June 2019 . In August 2019, AbbVie entered into an amended and restated $4.0 billion five-year revolving credit facility that matures in August 2024. This amended facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants, all of which the company was in compliance with as of September 30, 2019. No amounts were outstanding under the company's credit facilities as of September 30, 2019 and December 31, 2018 . In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a 364 -day bridge credit agreement and on July 12, 2019, AbbVie entered into a term loan credit agreement.

Post-Employment Benefits

Post-Employment Benefits	9 Months Ended
	Sep. 30, 2019
Postemployment Benefits [Abstract]
Post-Employment Benefits	Post-Employment Benefits The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans: Defined Other post- Three months ended Nine months ended Three months ended Nine months ended (in millions) 2019 2018 2019 2018 2019 2018 2019 2018 Service cost $ 67 $ 70 $ 202 $ 214 $ 6 $ 7 $ 19 $ 20 Interest cost 64 57 194 171 6 6 21 18 Expected return on plan assets (118 ) (109 ) (356 ) (330 ) — — — — Amortization of actuarial losses and prior service cost 27 38 82 114 1 — 1 1 Net periodic benefit cost $ 40 $ 56 $ 122 $ 169 $ 13 $ 13 $ 41 $ 39 The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.

Equity

Equity	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Equity	Equity Stock-Based Compensation Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows: Three months ended Nine months ended (in millions) 2019 2018 2019 2018 Cost of products sold $ 4 $ 7 $ 24 $ 23 Research and development 31 32 136 139 Selling, general and administrative 40 36 191 189 Pre-tax compensation expense 75 75 351 351 Tax benefit 15 13 64 61 After-tax compensation expense $ 60 $ 62 $ 287 $ 290 Stock Options During the nine months ended September 30, 2019 , primarily in connection with the company's annual grant, AbbVie granted 1.0 million stock options with a weighted-average grant-date fair value of $12.54 . As of September 30, 2019 , $7 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years . RSUs and Performance Shares During the nine months ended September 30, 2019 , primarily in connection with the company's annual grant, AbbVie granted 5.5 million RSUs and performance shares with a weighted-average grant-date fair value of $78.55 . As of September 30, 2019 , $365 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years . Cash Dividends The following table summarizes quarterly cash dividends declared during 2019 and 2018 : 2019 2018 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 11/01/19 02/14/20 $ 1.18 11/02/18 02/15/19 $ 1.07 09/06/19 11/15/19 $ 1.07 09/07/18 11/15/18 $ 0.96 06/20/19 08/15/19 $ 1.07 06/14/18 08/15/18 $ 0.96 02/21/19 05/15/19 $ 1.07 02/15/18 05/15/18 $ 0.96 Stock Repurchase Program The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under these programs are recorded at acquisition cost, including related expenses, and are available for general corporate purposes. AbbVie repurchased 4 million shares for $300 million during the nine months ended September 30, 2019 and 94 million shares for $9.8 billion during the nine months ended September 30, 2018 . AbbVie's remaining stock repurchase authorization was approximately $4.0 billion as of September 30, 2019 . Accumulated Other Comprehensive Loss The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2019 : (in millions) Foreign currency Net investment hedging activities Pension and post- Marketable security activities Cash flow hedging Total Balance as of December 31, 2018 $ (830 ) $ (65 ) $ (1,722 ) $ (10 ) $ 147 $ (2,480 ) Other comprehensive income (loss) before reclassifications (288 ) 199 12 12 77 12 Net losses (gains) reclassified from accumulated other comprehensive loss — (15 ) 66 (2 ) (109 ) (60 ) Net current-period other comprehensive income (loss) (288 ) 184 78 10 (32 ) (48 ) Balance as of September 30, 2019 $ (1,118 ) $ 119 $ (1,644 ) $ — $ 115 $ (2,528 ) Other comprehensive loss for the nine months ended September 30, 2019 included foreign currency translation adjustments totaling a loss of $288 million , which was principally due to the weakening of the Euro in the nine months ended September 30, 2019 on the translation of the company’s assets denominated in the Euro. The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2018 : (in millions) Foreign currency Net investment hedging activities Pension and post- Marketable security activities Cash flow hedging Total Balance as of December 31, 2017 $ (439 ) $ (203 ) $ (1,919 ) $ — $ (166 ) $ (2,727 ) Other comprehensive income (loss) before reclassifications (250 ) 73 7 (6 ) 110 (66 ) Net losses reclassified from accumulated other comprehensive loss — — 92 4 138 234 Net current-period other comprehensive income (loss) (250 ) 73 99 (2 ) 248 168 Balance as of September 30, 2018 $ (689 ) $ (130 ) $ (1,820 ) $ (2 ) $ 82 $ (2,559 ) Other comprehensive income for the nine months ended September 30, 2018 included foreign currency translation adjustments totaling a loss of $250 million , which was principally due to the weakening of the Euro in the nine months ended September 30, 2018 on the translation of the company’s assets denominated in the Euro. The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: Three months ended Nine months ended (in millions) (brackets denote gains) 2019 2018 2019 2018 Pension and post-employment benefits Amortization of actuarial losses and other (a) $ 28 $ 38 $ 83 $ 115 Tax benefit (5 ) (8 ) (17 ) (23 ) Total reclassifications, net of tax $ 23 $ 30 $ 66 $ 92 Cash flow hedging activities Losses (gains) on foreign currency forward exchange contracts (b) $ (42 ) $ 54 $ (119 ) $ 144 Tax expense (benefit) 3 — 10 (6 ) Total reclassifications, net of tax $ (39 ) $ 54 $ (109 ) $ 138 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (c) $ (10 ) $ — $ (19 ) $ — Tax expense 2 — 4 — Total reclassifications, net of tax $ (8 ) $ — $ (15 ) $ — (a) Amounts are included in the computation of net periodic benefit cost (see Note 10 ). (b) Amounts are included in cost of products sold (see Note 9 ). (c) Amounts are included in interest expense, net (see Note 9 ).

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rate was 6% for the three months and 5% for the nine months ended September 30, 2019 and 1% for the three and nine months ended September 30, 2018 . The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the benefit from foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions and business development activities. The increase in the effective tax rate for the three and nine months ended September 30, 2019 over the prior year was principally due to the beneficial impact of the timing of provisions of the Act related to earnings from certain foreign subsidiaries in prior year and changes in the jurisdictional mix of earnings, including a change in fair value of contingent consideration liabilities. These increases were partially offset by the favorable resolution of various tax positions in the current year. Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company’s gross unrecognized tax benefits balance may change within the next twelve months by up to $193 million .

Legal Proceedings and Contingen

Legal Proceedings and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. The recorded accrual balance for litigation was approximately $325 million as of September 30, 2019 and $350 million as of December 31, 2018 . Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows. Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters. Four lawsuits against Unimed Pharmaceuticals, LLC, Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) and others are consolidated for pre-trial purposes in the United States District Court for the Northern District of Georgia under the Multi-District Litigation (MDL) Rules as In re: AndroGel Antitrust Litigation , MDL No. 2084. These cases, brought by direct AndroGel purchasers, generally allege Solvay's 2006 patent litigation settlement agreements and related agreements with three generic companies violate federal antitrust laws. Plaintiffs seek monetary damages and attorneys' fees. In September 2014, the FTC filed a lawsuit, FTC v. AbbVie Inc., et al. , against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that the 2011 patent litigation with two generic companies regarding AndroGel was sham litigation and the settlements of that litigation violated federal antitrust law. In May 2015, the court dismissed the FTC’s settlement-related claim. In June 2018, following a bench trial, the court found for the FTC on its sham litigation claim and ordered a disgorgement remedy of $448 million , plus prejudgment interest. The court denied the FTC’s request for injunctive relief. AbbVie is appealing the court’s liability and disgorgement rulings and, based on an assessment of the merits of that appeal, no liability has been accrued for this matter. The FTC is also appealing aspects of the court’s trial ruling and the dismissal of its settlement-related claim. In July 2018, a purported class action was filed in the United States District Court for the Eastern District of Pennsylvania on behalf of direct AndroGel purchasers based on the trial court’s ruling in the FTC’s case. In September 2019, two individual direct AndroGel purchasers substituted in as the plaintiffs in that lawsuit and withdrew the class allegations. That case, now pending as Rochester Drug Co-Operative, Inc., et al. v. AbbVie Inc., et al. , is stayed pending the appeals in the FTC’s case. In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. , against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, making allegations similar to those in In re: AndroGel Antitrust Litigation (No. II) , MDL No. 2084 (above) and FTC v. AbbVie Inc. (above). Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payers. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as In re: Niaspan Antitrust Litigation , MDL No. 2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In May 2018, the California Court of Appeal ruled that the District Attorney’s Office may not bring monetary claims beyond the scope of Orange County, which the District Attorney’s Office is appealing. In January and February 2019, two shareholder derivative lawsuits, Brown v. Gonzalez, et al., and Elfers v. Gonzalez, et al. , were filed in the United States District Court for the Northern District of Illinois, alleging that certain AbbVie directors and officers breached their fiduciary duties in connection with HUMIRA patient and reimbursement support services and other services and items of value, as alleged in the State of California case discussed below. The lawsuits were consolidated and, on August 19, 2019, the court granted the plaintiffs’ voluntary dismissal motion. Between March and May 2019, 12 putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect HUMIRA purchasers, alleging that AbbVie’s settlements with biosimilar manufacturers and AbbVie’s HUMIRA patent portfolio violate state and federal antitrust laws. The court consolidated these lawsuits as In re: Humira (Adalimumab) Antitrust Litigation . In November 2014, a putative class action lawsuit, Medical Mutual of Ohio v. AbbVie Inc., et al. , was filed against several manufacturers of testosterone replacement therapies (TRTs), including AbbVie, in the United States District Court for the Northern District of Illinois on behalf of all insurance companies, health benefit providers, and other third party payers who paid for TRTs, including AndroGel. The claims asserted include violations of the federal RICO Act and state consumer fraud and deceptive trade practices laws. The complaint seeks monetary damages and injunctive relief. In July 2018, the court denied the plaintiff’s motion for class certification. In February 2019, the court granted the defendants’ summary judgment motion, which the plaintiff appealed to the United States Court of Appeals for the Seventh Circuit. In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al. , in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico’s Unfair Practices Act. In September 2018, the Commissioner of the California Department of Insurance intervened in a qui tam lawsuit, State of California and Lazaro Suarez v. AbbVie Inc., et al. , brought under the California Insurance Frauds Prevention Act, in California Superior Court for Alameda County. The Department of Insurance’s complaint alleges that, through patient and reimbursement support services and other services and items of value provided in connection with HUMIRA, AbbVie caused the submission of fraudulent commercial insurance claims for HUMIRA in violation of the California statute. The complaint seeks injunctive relief, an assessment of up to three times the amount of the claims at issue, and civil penalties. In addition, a federal securities lawsuit ( Holwill v. AbbVie Inc., et al .) is pending in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for HUMIRA sales growth in financial filings between 2013 and 2017 were misleading because they omitted the conduct alleged in the Department of Insurance’s complaint. In November 2014, five individuals filed a putative class action lawsuit, Rubinstein, et al. v Gonzalez, et al., on behalf of purchasers and sellers of certain Shire plc (Shire) securities between June 20 and October 14, 2014, against AbbVie and its chief executive officer in the United States District Court for the Northern District of Illinois alleging that the defendants made and/or are responsible for material misstatements in violation of federal securities laws in connection with AbbVie's proposed transaction with Shire. In October 2019, the court granted final approval to the parties’ class settlement agreement. In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc. , was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connec tion with its proposed t ransaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. Plaintiffs seek compensatory and punitive damages. Product liability cases were filed in which plaintiffs generally allege that AbbVie and other manufacturers of TRTs did not adequately warn about risks of certain injuries, primarily heart attacks, strokes and blood clots. Approximately 3,900 claims against AbbVie are consolidated for pre-trial purposes in the United States District Court for the Northern District of Illinois under the MDL Rules as In re: Testosterone Replacement Therapy Products Liability Litigation , MDL No. 2545. Approximately 200 claims against AbbVie are pending in various state courts. Plaintiffs generally seek compensatory and punitive damages. In November 2018, AbbVie entered into a Master Settlement Agreement with the Plaintiffs’ Steering Committee in the MDL encompassing existing claims in all courts. All proceedings in pending cases are effectively stayed during the settlement administration process. Product liability cases are pending in which plaintiffs generally allege that AbbVie did not adequately warn about risk of certain injuries, primarily various birth defects, arising from use of Depakote. Approximately 150 cases are pending in the United States District Court for the Southern District of Illinois, and approximately seven others are pending in various federal and state courts. Plaintiffs generally seek compensatory and punitive damages. Approximately ninety percent of these pending cases, plus other unfiled claims, are subject to confidential settlement agreements and are expected to be dismissed with prejudice. Beginning in May 2016, the Patent Trial & Appeal Board of the U.S. Patent & Trademark Office (PTO) instituted five inter partes review proceedings brought by Coherus Biosciences and Boehringer Ingelheim related to three AbbVie patents covering methods of treatment of rheumatoid arthritis using adalimumab. In these proceedings, the PTO reviewed the validity of the patents and issued decisions of invalidity in May, June and July of 2017. AbbVie’s appeal of the decisions is pending in the Court of Appeals for the Federal Circuit. In March 2017, AbbVie filed a lawsuit, AbbVie Inc. v. Novartis Vaccines and Diagnostics, Inc. and Grifols Worldwide Operations Ltd., in the United States District Court for the Northern District of California against Novartis Vaccines and Grifols Worldwide seeking a declaratory judgment that 11 HCV-related patents licensed to AbbVie in 2002 are invalid. Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib capsules (a drug Pharmacyclics sells under the trademark IMBRUVICA®). In February 2018, cases were filed in the United States District Court for the District of Delaware against the following defendants: Fresenius Kabi USA, LLC, Fresenius Kabi USA, Inc., and Fresenius Kabi Oncology Limited; Sun Pharma Global FZE and Sun Pharmaceutical Industries Ltd.; Cipla Limited and Cipla USA Inc.; and Zydus Worldwide DMCC, Cadila Healthcare Limited, Sandoz Inc., and Lek Pharmaceuticals D.D. In each case, Pharmacyclics alleges the defendant’s proposed generic ibrutinib product infringes certain Pharmacyclics patents and seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA, is the co-plaintiff in these suits. Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark IMBRUVICA®). In a case filed in the United States District Court for the District of Delaware in March 2019, Pharmacyclics alleges that Alvogen Pine Brook LLC’s and Natco Pharma Ltd.’s proposed generic ibrutinib tablet product infringes certain Pharmacyclics patents. Pharmacyclics seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA, is the co-plaintiff in this suit.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Segment Information	Segment Information AbbVie operates in one business segment—pharmaceutical products. The following table details AbbVie’s worldwide net revenues: Three months ended Nine months ended (in millions) 2019 2018 2019 2018 Immunology HUMIRA United States $ 3,887 $ 3,546 $ 10,895 $ 10,070 International 1,049 1,578 3,357 4,948 Total $ 4,936 $ 5,124 $ 14,252 $ 15,018 SKYRIZI United States $ 76 $ — $ 118 $ — International 15 — 21 — Total $ 91 $ — $ 139 $ — RINVOQ United States $ 14 $ — $ 14 $ — Hematologic Oncology IMBRUVICA United States $ 1,042 $ 812 $ 2,757 $ 2,129 Collaboration revenues 215 160 621 455 Total $ 1,257 $ 972 $ 3,378 $ 2,584 VENCLEXTA United States $ 142 $ 69 $ 364 $ 157 International 79 27 177 63 Total $ 221 $ 96 $ 541 $ 220 HCV MAVYRET United States $ 368 $ 444 $ 1,167 $ 1,206 International 327 395 1,098 1,413 Total $ 695 $ 839 $ 2,265 $ 2,619 VIEKIRA United States $ — $ — $ — $ 3 International 3 23 32 132 Total $ 3 $ 23 $ 32 $ 135 Other Key Products Creon United States $ 265 $ 239 $ 749 $ 667 Lupron United States $ 187 $ 173 $ 546 $ 530 International 43 41 122 126 Total $ 230 $ 214 $ 668 $ 656 Synthroid United States $ 197 $ 192 $ 582 $ 567 Synagis International $ 132 $ 97 $ 457 $ 462 Duodopa United States $ 26 $ 19 $ 72 $ 57 International 91 87 271 260 Total $ 117 $ 106 $ 343 $ 317 Sevoflurane United States $ 18 $ 18 $ 53 $ 54 International 66 68 214 251 Total $ 84 $ 86 $ 267 $ 305 Kaletra United States $ 7 $ 16 $ 30 $ 42 International 67 72 199 210 Total $ 74 $ 88 $ 229 $ 252 AndroGel United States $ 53 $ 135 $ 149 $ 393 ORILISSA United States $ 27 $ 3 $ 58 $ 3 International — — 1 — Total $ 27 $ 3 $ 59 $ 3 All other $ 83 $ 22 $ 438 $ 250 Total net revenues $ 8,479 $ 8,236 $ 24,562 $ 24,448

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU No. 2016-02 In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) . The standard outlined a comprehensive lease accounting model that superseded the previous lease guidance and required lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms greater than 12 months. The guidance also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. AbbVie adopted the standard in the first quarter of 2019 using the modified retrospective method. Results for reporting periods beginning after December 31, 2018 have been presented in accordance with the standard, while results for prior periods have not been adjusted and continue to be reported in accordance with AbbVie's historical accounting. The cumulative effect of initially applying the new leases standard was recognized as an adjustment to the opening condensed consolidated balance sheet as of January 1, 2019. The company elected a package of practical expedients for leases that commenced prior to January 1, 2019 and did not reassess historical conclusions on: (i) whether any expired or existing contracts are or contain leases; (ii) lease classification for any expired or existing leases; and (iii) initial direct costs capitalization for any existing leases. Under the new standard, on January 1, 2019, the company recognized a cumulative-effect adjustment to its condensed consolidated balance sheet primarily related to the recognition of liabilities and corresponding right-of-use assets for operating leases. The adjustment to the condensed consolidated balance sheet included: (i) a $405 million increase to other assets; (ii) a $115 million increase to accounts payable and accrued liabilities; and (iii) a $290 million increase to other long-term liabilities. Other cumulative-effect adjustments to the condensed consolidated balance sheet were insignificant. Adoption of the standard did not have a significant impact on AbbVie's condensed consolidated statements of earnings for the three and nine months ended September 30, 2019 . ASU No. 2018-02 In February 2018, the FASB issued ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allowed a reclassification from accumulated other comprehensive income (AOCI) to retained earnings for stranded tax effects related to adjustments to deferred taxes resulting from the December 2017 enactment of the Tax Cuts and Jobs Act (the Act). AbbVie adopted the standard in the first quarter of 2019. Upon adoption, the company made an election to not reclassify the income tax effects of the Act from AOCI to retained earnings. Therefore, the adoption of the standard had no impact on AbbVie's consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted ASU No. 2016-13 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) . The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. Additionally, the standard requires new disclosures and will be effective for AbbVie starting with the first quarter of 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact to retained earnings as of the beginning of the fiscal year of adoption. AbbVie is currently assessing the impact of adopting this guidance but does not expect a material impact on its consolidated financial statements based on the company’s current portfolio of financial assets.

Leases (Policies)

Leases (Policies)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	Short-term leases with a term of 12 months or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components. The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option. Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants.
Short-Term Leases	Short-term leases with a term of 12 months

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	9 Months Ended
	Sep. 30, 2019
Supplemental Financial Information
Schedule of interest expense, net	Interest Expense, Net Three months ended Nine months ended (in millions) 2019 2018 2019 2018 Interest expense $ 480 $ 339 $ 1,225 $ 968 Interest income (60 ) (37 ) (171 ) (143 ) Interest expense, net $ 420 $ 302 $ 1,054 $ 825
Schedule of inventories	Inventories (in millions) September 30, 2019 December 31, 2018 Finished goods $ 449 $ 473 Work-in-process 1,120 862 Raw materials 360 270 Inventories $ 1,929 $ 1,605
Schedule of property and equipment	Property and Equipment (in millions) September 30, 2019 December 31, 2018 Property and equipment, gross $ 8,492 $ 8,396 Accumulated depreciation (5,598 ) (5,513 ) Property and equipment, net $ 2,894 $ 2,883

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Schedule of diluted earnings per share, impact of two-class method	The following table summarizes the impact of the two-class method: Three months ended Nine months ended (in millions, except per share data) 2019 2018 2019 2018 Basic EPS Net earnings $ 1,884 $ 2,747 $ 5,081 $ 7,513 Earnings allocated to participating securities 10 12 27 34 Earnings available to common shareholders $ 1,874 $ 2,735 $ 5,054 $ 7,479 Weighted-average basic shares outstanding 1,481 1,511 1,480 1,556 Basic earnings per share $ 1.27 $ 1.81 $ 3.41 $ 4.81 Diluted EPS Net earnings $ 1,884 $ 2,747 $ 5,081 $ 7,513 Earnings allocated to participating securities 10 12 27 34 Earnings available to common shareholders $ 1,874 $ 2,735 $ 5,054 $ 7,479 Weighted-average shares of common stock outstanding 1,481 1,511 1,480 1,556 Effect of dilutive securities 2 4 3 5 Weighted-average diluted shares outstanding 1,483 1,515 1,483 1,561 Diluted earnings per share $ 1.26 $ 1.81 $ 3.41 $ 4.79

Collaboration with Janssen Bi_2

Collaboration with Janssen Biotech, Inc. (Tables)	9 Months Ended
	Sep. 30, 2019
Collaboration with Janssen Biotech, Inc.
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Janssen and AbbVie: Three months ended Nine months ended (in millions) 2019 2018 2019 2018 United States - Janssen's share of profits (included in cost of products sold) $ 489 $ 377 $ 1,297 $ 978 International - AbbVie's share of profits (included in net revenues) 215 160 621 455 Global - AbbVie's share of other costs (included in respective line items) 81 81 230 232

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of changes in the carrying amount of goodwill	The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2018 $ 15,663 Foreign currency translation adjustments (126 ) Balance as of September 30, 2019 $ 15,537
Summary of definite-lived intangible assets	The following table summarizes intangible assets: September 30, 2019 December 31, 2018 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 19,600 $ (6,208 ) $ 13,392 $ 15,872 $ (5,614 ) $ 10,258 License agreements 7,798 (2,154 ) 5,644 7,865 (1,810 ) 6,055 Total definite-lived intangible assets 27,398 (8,362 ) 19,036 23,737 (7,424 ) 16,313 Indefinite-lived research and development — — — 4,920 — 4,920 Total intangible assets, net $ 27,398 $ (8,362 ) $ 19,036 $ 28,657 $ (7,424 ) $ 21,233
Summary of indefinite-lived intangible assets	The following table summarizes intangible assets: September 30, 2019 December 31, 2018 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 19,600 $ (6,208 ) $ 13,392 $ 15,872 $ (5,614 ) $ 10,258 License agreements 7,798 (2,154 ) 5,644 7,865 (1,810 ) 6,055 Total definite-lived intangible assets 27,398 (8,362 ) 19,036 23,737 (7,424 ) 16,313 Indefinite-lived research and development — — — 4,920 — 4,920 Total intangible assets, net $ 27,398 $ (8,362 ) $ 19,036 $ 28,657 $ (7,424 ) $ 21,233

Restructuring Plans (Tables)

Restructuring Plans (Tables)	9 Months Ended
	Sep. 30, 2019
Restructuring and Related Activities [Abstract]
Summary of the cash activity in the restructuring reserve	The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2019 : (in millions) Accrued balance as of December 31, 2018 $ 99 Restructuring charges 194 Payments and other adjustments (133 ) Accrued balance as of September 30, 2019 $ 160

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Summary of amounts and location of operating and finance leases on the condensed consolidated balance sheet	The following table summarizes the amounts and location of operating and finance leases on the condensed consolidated balance sheet: (in millions) Balance sheet caption September 30, Assets Operating Other assets $ 357 Finance Property and equipment, net 24 Total lease assets $ 381 Liabilities Operating Current Accounts payable and accrued liabilities $ 107 Noncurrent Other long-term liabilities 268 Finance Current Current portion of long-term debt and finance lease obligations 7 Noncurrent Long-term debt and finance lease obligations 21 Total lease liabilities $ 403
Summary of lease costs recognized in the condensed consolidated statement of earnings	The following table summarizes the lease costs recognized in the condensed consolidated statements of earnings: Three months ended Nine months ended (in millions) 2019 2019 Operating lease cost $ 30 $ 94 Short-term lease cost 9 24 Variable lease cost 17 46 Total lease cost $ 56 $ 164
Schedule of weighted-average remaining lease term and weighted-average discount rate for operating and finance leases	The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases: September 30, Weighted-average remaining lease term (in years) Operating 6 Finance 3 Weighted-average discount rate Operating 4.0 % Finance 4.0 %
Schedule of supplementary cash flow information regarding the company's leases	The following table presents supplementary cash flow information regarding the company's leases: Nine months ended (in millions) 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 94 Right-of-use assets obtained in exchange for new operating lease liabilities 16
Summary of future maturities of AbbVie's operating lease liabilities	The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of September 30, 2019 : (in millions) Operating leases Finance leases Total (a)(b) 2019 $ 32 $ 6 $ 38 2020 116 10 126 2021 99 9 108 2022 56 3 59 2023 35 1 36 Thereafter 80 — 80 Total lease payments 418 29 447 Less: Interest 43 1 44 Present value of lease liabilities $ 375 $ 28 $ 403
Summary of future maturities of AbbVie's finance lease liabilities	The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of September 30, 2019 : (in millions) Operating leases Finance leases Total (a)(b) 2019 $ 32 $ 6 $ 38 2020 116 10 126 2021 99 9 108 2022 56 3 59 2023 35 1 36 Thereafter 80 — 80 Total lease payments 418 29 447 Less: Interest 43 1 44 Present value of lease liabilities $ 375 $ 28 $ 403

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measures (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Summary of amounts and location of derivatives on the condensed consolidated balance sheets	The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets: Fair value – Fair value – (in millions) Balance sheet caption September 30, December 31, 2018 Balance sheet caption September 30, December 31, 2018 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 4 $ 113 Accounts payable and accrued liabilities $ — $ — Designated as net investment hedges Prepaid expenses and 69 — Accounts payable and accrued liabilities — — Not designated as hedges Prepaid expenses and other 13 19 Accounts payable and accrued liabilities 37 26 Treasury rate lock agreements designated as cash flow hedges Prepaid expenses and other 123 — Accounts payable and accrued liabilities 35 — Interest rate swaps designated as fair value hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 8 — Interest rate swaps designated as fair value hedges Other assets 44 — Other long-term liabilities 59 466 Total derivatives $ 253 $ 132 $ 139 $ 492
Schedule of pre-tax amounts of derivatives recognized in other comprehensive income (loss)	The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss): Three months ended Nine months ended (in millions) 2019 2018 2019 2018 Foreign currency forward exchange contracts Designated as cash flow hedges $ 3 $ 1 $ 8 $ 122 Designated as net investment hedges 59 — 69 — Treasury rate lock agreements designated as cash flow hedges 88 — 88 —
Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings	The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 11 for the amount of net gains (losses) reclassified out of AOCI. Three months ended Nine months ended (in millions) Statement of earnings caption 2019 2018 2019 2018 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ 42 $ (54 ) $ 119 $ (144 ) Designated as net investment hedges Interest expense, net 10 — 19 — Not designated as hedges Net foreign exchange loss (55 ) 22 (95 ) 91 Interest rate swaps designated as fair value hedges Interest expense, net 78 (63 ) 443 (306 ) Debt designated as hedged item in fair value hedges Interest expense, net (78 ) 63 (443 ) 306
Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis	The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of September 30, 2019 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant Assets Cash and equivalents $ 10,648 $ 1,288 $ 9,360 $ — Debt securities 2 — 2 — Equity securities 62 62 — — Interest rate hedges 44 — 44 — Foreign currency contracts 86 — 86 — Treasury rate lock agreements 123 — 123 — Total assets $ 10,965 $ 1,350 $ 9,615 $ — Liabilities Interest rate hedges $ 67 $ — $ 67 $ — Foreign currency contracts 37 — 37 — Treasury rate lock agreements 35 — 35 — Contingent consideration 6,957 — — 6,957 Total liabilities $ 7,096 $ — $ 139 $ 6,957 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2018 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant Assets Cash and equivalents $ 7,289 $ 1,209 $ 6,080 $ — Time deposits 568 — 568 — Debt securities 1,536 — 1,536 — Equity securities 4 4 — — Foreign currency contracts 132 — 132 — Total assets $ 9,529 $ 1,213 $ 8,316 $ — Liabilities Interest rate hedges $ 466 $ — $ 466 $ — Foreign currency contracts 26 — 26 — Contingent consideration 4,483 — — 4,483 Total liabilities $ 4,975 $ — $ 492 $ 4,483
Schedule of changes in fair value of Level 3 inputs	The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs: Nine months ended (in millions) 2019 2018 Beginning balance $ 4,483 $ 4,534 Change in fair value recognized in net earnings 2,653 432 Payments (179 ) (100 ) Ending balance $ 6,957 $ 4,866
Schedule of book values, approximate fair values and bases used to measure certain financial instruments	The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of September 30, 2019 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant observable Significant Liabilities Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 5,284 $ 5,293 $ 5,286 $ 7 $ — Long-term debt and finance lease obligations, excluding fair value hedges 33,141 34,964 34,943 21 — Total liabilities $ 38,425 $ 40,257 $ 40,229 $ 28 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2018 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant observable Significant Liabilities Short-term borrowings $ 3,699 $ 3,693 $ — $ 3,693 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 1,609 1,617 1,609 8 — Long-term debt and finance lease obligations, excluding fair value hedges 35,468 34,052 34,024 28 — Total liabilities $ 40,776 $ 39,362 $ 35,633 $ 3,729 $ —
Summary of available-for-sale securities by type	The following table summarizes available-for-sale securities by type as of December 31, 2018 : Amortized cost Gross unrealized Fair value (in millions) Gains Losses Asset backed securities $ 423 $ — $ (2 ) $ 421 Corporate debt securities 1,042 1 (9 ) 1,034 Other debt securities 81 — — 81 Total $ 1,546 $ 1 $ (11 ) $ 1,536

Post-Employment Benefits (Table

Post-Employment Benefits (Tables)	9 Months Ended
	Sep. 30, 2019
Postemployment Benefits [Abstract]
Summary of net periodic benefit costs	The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans: Defined Other post- Three months ended Nine months ended Three months ended Nine months ended (in millions) 2019 2018 2019 2018 2019 2018 2019 2018 Service cost $ 67 $ 70 $ 202 $ 214 $ 6 $ 7 $ 19 $ 20 Interest cost 64 57 194 171 6 6 21 18 Expected return on plan assets (118 ) (109 ) (356 ) (330 ) — — — — Amortization of actuarial losses and prior service cost 27 38 82 114 1 — 1 1 Net periodic benefit cost $ 40 $ 56 $ 122 $ 169 $ 13 $ 13 $ 41 $ 39

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Summary of share-based compensation expense	Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows: Three months ended Nine months ended (in millions) 2019 2018 2019 2018 Cost of products sold $ 4 $ 7 $ 24 $ 23 Research and development 31 32 136 139 Selling, general and administrative 40 36 191 189 Pre-tax compensation expense 75 75 351 351 Tax benefit 15 13 64 61 After-tax compensation expense $ 60 $ 62 $ 287 $ 290
Summary of quarterly cash dividends	The following table summarizes quarterly cash dividends declared during 2019 and 2018 : 2019 2018 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 11/01/19 02/14/20 $ 1.18 11/02/18 02/15/19 $ 1.07 09/06/19 11/15/19 $ 1.07 09/07/18 11/15/18 $ 0.96 06/20/19 08/15/19 $ 1.07 06/14/18 08/15/18 $ 0.96 02/21/19 05/15/19 $ 1.07 02/15/18 05/15/18 $ 0.96
Summary of changes in balances of each component of accumulated other comprehensive loss	The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2018 : (in millions) Foreign currency Net investment hedging activities Pension and post- Marketable security activities Cash flow hedging Total Balance as of December 31, 2017 $ (439 ) $ (203 ) $ (1,919 ) $ — $ (166 ) $ (2,727 ) Other comprehensive income (loss) before reclassifications (250 ) 73 7 (6 ) 110 (66 ) Net losses reclassified from accumulated other comprehensive loss — — 92 4 138 234 Net current-period other comprehensive income (loss) (250 ) 73 99 (2 ) 248 168 Balance as of September 30, 2018 $ (689 ) $ (130 ) $ (1,820 ) $ (2 ) $ 82 $ (2,559 ) The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2019 : (in millions) Foreign currency Net investment hedging activities Pension and post- Marketable security activities Cash flow hedging Total Balance as of December 31, 2018 $ (830 ) $ (65 ) $ (1,722 ) $ (10 ) $ 147 $ (2,480 ) Other comprehensive income (loss) before reclassifications (288 ) 199 12 12 77 12 Net losses (gains) reclassified from accumulated other comprehensive loss — (15 ) 66 (2 ) (109 ) (60 ) Net current-period other comprehensive income (loss) (288 ) 184 78 10 (32 ) (48 ) Balance as of September 30, 2019 $ (1,118 ) $ 119 $ (1,644 ) $ — $ 115 $ (2,528 )
Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss	The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: Three months ended Nine months ended (in millions) (brackets denote gains) 2019 2018 2019 2018 Pension and post-employment benefits Amortization of actuarial losses and other (a) $ 28 $ 38 $ 83 $ 115 Tax benefit (5 ) (8 ) (17 ) (23 ) Total reclassifications, net of tax $ 23 $ 30 $ 66 $ 92 Cash flow hedging activities Losses (gains) on foreign currency forward exchange contracts (b) $ (42 ) $ 54 $ (119 ) $ 144 Tax expense (benefit) 3 — 10 (6 ) Total reclassifications, net of tax $ (39 ) $ 54 $ (109 ) $ 138 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (c) $ (10 ) $ — $ (19 ) $ — Tax expense 2 — 4 — Total reclassifications, net of tax $ (8 ) $ — $ (15 ) $ — (a) Amounts are included in the computation of net periodic benefit cost (see Note 10 ). (b) Amounts are included in cost of products sold (see Note 9 ). (c) Amounts are included in interest expense, net (see Note 9 ).

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Schedule of worldwide net revenues	AbbVie operates in one business segment—pharmaceutical products. The following table details AbbVie’s worldwide net revenues: Three months ended Nine months ended (in millions) 2019 2018 2019 2018 Immunology HUMIRA United States $ 3,887 $ 3,546 $ 10,895 $ 10,070 International 1,049 1,578 3,357 4,948 Total $ 4,936 $ 5,124 $ 14,252 $ 15,018 SKYRIZI United States $ 76 $ — $ 118 $ — International 15 — 21 — Total $ 91 $ — $ 139 $ — RINVOQ United States $ 14 $ — $ 14 $ — Hematologic Oncology IMBRUVICA United States $ 1,042 $ 812 $ 2,757 $ 2,129 Collaboration revenues 215 160 621 455 Total $ 1,257 $ 972 $ 3,378 $ 2,584 VENCLEXTA United States $ 142 $ 69 $ 364 $ 157 International 79 27 177 63 Total $ 221 $ 96 $ 541 $ 220 HCV MAVYRET United States $ 368 $ 444 $ 1,167 $ 1,206 International 327 395 1,098 1,413 Total $ 695 $ 839 $ 2,265 $ 2,619 VIEKIRA United States $ — $ — $ — $ 3 International 3 23 32 132 Total $ 3 $ 23 $ 32 $ 135 Other Key Products Creon United States $ 265 $ 239 $ 749 $ 667 Lupron United States $ 187 $ 173 $ 546 $ 530 International 43 41 122 126 Total $ 230 $ 214 $ 668 $ 656 Synthroid United States $ 197 $ 192 $ 582 $ 567 Synagis International $ 132 $ 97 $ 457 $ 462 Duodopa United States $ 26 $ 19 $ 72 $ 57 International 91 87 271 260 Total $ 117 $ 106 $ 343 $ 317 Sevoflurane United States $ 18 $ 18 $ 53 $ 54 International 66 68 214 251 Total $ 84 $ 86 $ 267 $ 305 Kaletra United States $ 7 $ 16 $ 30 $ 42 International 67 72 199 210 Total $ 74 $ 88 $ 229 $ 252 AndroGel United States $ 53 $ 135 $ 149 $ 393 ORILISSA United States $ 27 $ 3 $ 58 $ 3 International — — 1 — Total $ 27 $ 3 $ 59 $ 3 All other $ 83 $ 22 $ 438 $ 250 Total net revenues $ 8,479 $ 8,236 $ 24,562 $ 24,448

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Millions	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle
Other assets	$ 1,677		$ 1,208
Accounts payable and accrued liabilities	12,217		11,931
Other long-term liabilities	$ 15,990		$ 14,490
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle
Other assets		$ 405
Accounts payable and accrued liabilities		115
Other long-term liabilities		$ 290

Supplemental Financial Inform_3

Supplemental Financial Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Interest Expense, Net
Interest expense	$ 480	$ 339	$ 1,225	$ 968
Interest income	(60)	(37)	(171)	(143)
Interest expense, net	420	302	1,054	825
Inventories
Finished goods	449		449		$ 473
Work-in-process	1,120		1,120		862
Raw materials	360		360		270
Inventories	1,929		1,929		1,605
Property and Equipment
Property and equipment, gross	8,492		8,492		8,396
Accumulated depreciation	(5,598)		(5,598)		(5,513)
Property and equipment, net	2,894		2,894		$ 2,883
Depreciation expense	$ 114	$ 115	$ 346	$ 349

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Basic EPS
Net earnings	$ 1,884	$ 2,747	$ 5,081	$ 7,513
Earnings allocated to participating securities	10	12	27	34
Earnings available to common shareholders	$ 1,874	$ 2,735	$ 5,054	$ 7,479
Weighted-average basic shares outstanding (in shares)	1,481	1,511	1,480	1,556
Basic earnings per share (in dollars per share)	$ 1.27	$ 1.81	$ 3.41	$ 4.81
Diluted EPS
Net earnings	$ 1,884	$ 2,747	$ 5,081	$ 7,513
Earnings allocated to participating securities	10	12	27	34
Earnings available to common shareholders	$ 1,874	$ 2,735	$ 5,054	$ 7,479
Weighted-average basic shares outstanding (in shares)	1,481	1,511	1,480	1,556
Effect of dilutive securities (in shares)	2	4	3	5
Weighted-average diluted shares outstanding (in shares)	1,483	1,515	1,483	1,561
Diluted earnings per share (in dollars per share)	$ 1.26	$ 1.81	$ 3.41	$ 4.79

Licensing, Acquisitions, and _2

Licensing, Acquisitions, and Other Arrangements - Proposed Acquisition of Allergan plc (Details) $ / shares in Units, € in Billions	Jul. 12, 2019USD ($)	Jun. 25, 2019USD ($)	Mar. 31, 2020USD ($)	Sep. 30, 2019USD ($)	Jan. 01, 2020$ / sharesshares	Oct. 25, 2019USD ($)	Oct. 25, 2019EUR (€)	Jun. 24, 2019$ / shares
Business Acquisition
Closing price of AbbVie's common stock | $ / shares								$ 78.45
Subsequent event | Senior notes
Business Acquisition
Principal amount of term loan						$ 15,500,000,000	€ 3.7
June 2019 bridge credit agreement | Bridge credit agreement
Business Acquisition
Bridge credit agreement maximum borrowing capacity	$ 32,000,000,000	$ 38,000,000,000
Credit agreement term		364 days
Amount drawn under credit agreement				$ 0
July 2019 term loan agreement | Term loan agreement
Business Acquisition
Principal amount of term loan	$ 6,000,000,000
Amount drawn under credit agreement				$ 0
July 2019 364-day term loan tranche | Term loan agreement
Business Acquisition
Credit agreement term	364 days
Principal amount of term loan	$ 1,500,000,000
July 2019 three-year term loan tranche | Term loan agreement
Business Acquisition
Credit agreement term	3 years
Principal amount of term loan	$ 2,500,000,000
July 2019 five-year term loan tranche | Term loan agreement
Business Acquisition
Credit agreement term	5 years
Principal amount of term loan	$ 2,000,000,000
Allergan plc | Scenario, forecast
Business Acquisition
Total consideration			$ 63,000,000,000
Shares of AbbVie stock received by Allergan shareholders | shares					0.8660
Cash per share received by Allergan shareholders | $ / shares					$ 120.30

Licensing, Acquisitions, and _3

Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 31, 2019	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative and license agreements
Cash outflows related to acquisitions and investments					$ 476	$ 541
Acquired in-process research and development			$ 0	$ 55	246	124
Other expense			$ 0	$ 0	$ 0	500
Collaborative arrangement
Collaborative and license agreements
Additional contribution to collaboration		$ 500
Calico Life Sciences Llc | Collaborative arrangement
Collaborative and license agreements
Additional contribution to collaboration by partner		$ 500
Term by which the agreement was extended		3 years
Other expense						$ 500
Other income | Subsequent event | Reata Pharmaceuticals, Inc.
Collaborative and license agreements
Consideration receivable for reacquired rights	$ 330

Collaboration with Janssen Bi_3

Collaboration with Janssen Biotech, Inc. (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Collaborative and license agreements
Accounts receivable, net	$ 5,529		$ 5,529		$ 5,384
Accounts payable and accrued liabilities	12,217		$ 12,217		11,931
Collaborative arrangement
Collaborative and license agreements
Share of collaboration development costs responsible by the entity (as a percent)			40.00%
Global - AbbVie's share of other costs (included in respective line items)	81	$ 81	$ 230	$ 232
Collaborative arrangement | International
Collaborative and license agreements
International - AbbVie's share of profits (included in net revenues)	215	160	621	455
Janssen Biotech Inc | Collaborative arrangement
Collaborative and license agreements
Milestone payments	200		$ 200
Share of collaboration development costs responsible by Janssen (as a percent)			60.00%
Accounts receivable, net	235		$ 235		177
Accounts payable and accrued liabilities	467		467		$ 376
Janssen Biotech Inc | Collaborative arrangement | United States
Collaborative and license agreements
United States - Janssen's share of profits (included in cost of products sold)	$ 489	$ 377	$ 1,297	$ 978

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Changes in the carrying amount of goodwill
Balance at the beginning of the period	$ 15,663,000,000
Foreign currency translation adjustments	(126,000,000)
Balance at the end of the period	15,537,000,000
Accumulated goodwill impairment losses
Accumulated goodwill impairment losses	$ 0

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets
Gross carrying amount	$ 27,398	$ 23,737
Accumulated amortization	(8,362)	(7,424)
Net carrying amount	19,036	16,313
Indefinite-lived research and development	0	4,920
Total intangible assets gross carrying amount	27,398	28,657
Total intangible assets, net	19,036	21,233
Developed product rights
Finite-Lived Intangible Assets
Gross carrying amount	19,600	15,872
Accumulated amortization	(6,208)	(5,614)
Net carrying amount	13,392	10,258
License agreements
Finite-Lived Intangible Assets
Gross carrying amount	7,798	7,865
Accumulated amortization	(2,154)	(1,810)
Net carrying amount	$ 5,644	$ 6,055

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Indefinite-Lived Intangible Assets (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Indefinite-lived Intangible Assets
Indefinite-lived intangible asset impairment charges			$ 0	$ 1,000,000,000	$ 0
In-Process Research and Development | Stemcentrx Inc.
Indefinite-lived Intangible Assets
Indefinite-lived intangible asset impairment charges		$ 1,000,000,000
SKYRIZI
Indefinite-lived Intangible Assets
Reclassification from indefinite-lived intangible assets	$ (3,900,000,000)

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Definite-Lived Intangible Assets (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Finite-Lived Intangible Assets
Amortization expense		$ 389,000,000	$ 320,000,000	$ 1,162,000,000	$ 974,000,000
Definite-lived intangible assets impairment charges		$ 0	$ 0	$ 0	$ 0
SKYRIZI | Developed product rights
Finite-Lived Intangible Assets
Reclassification to definite-lived intangible assets	$ 3,900,000,000

Restructuring Plans (Details)

Restructuring Plans (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring charges	$ 22	$ 22	$ 208	$ 45
Restructuring reserve activity
Accrued balance beginning of the period			99
Restructuring charges			(194)
Payments and other adjustments			(133)
Accrued balance end of the period	$ 160		$ 160

Leases - Balance Sheet Disclosu

Leases - Balance Sheet Disclosure (Details) $ in Millions	Sep. 30, 2019USD ($)
Assets
Total lease assets	$ 381
Liabilities
Total lease liabilities	403	[1],[2]
Other assets
Assets
Operating lease assets	357
Property and equipment, net
Assets
Finance lease assets	24
Accounts payable and accrued liabilities
Liabilities
Current operating lease liabilities	107
Other long-term liabilities
Liabilities
Noncurrent operating lease liabilities	268
Current portion of long-term debt and finance lease obligations
Liabilities
Current finance lease liabilities	7
Long-term debt and finance lease obligations
Liabilities
Noncurrent finance lease liabilities	$ 21
[1]	Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.
[2]	Total lease payments exclude approximately $350 million of contractual minimum lease payments for leases executed but not yet commenced. These leases will commence between years 2019 and 2020 with lease terms of approximately 11 years .

Leases - Cost (Details)

Leases - Cost (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Leases [Abstract]
Operating lease cost	$ 30	$ 94
Short-term lease cost	9	24
Variable lease cost	17	46
Total lease cost	$ 56	$ 164

Leases - Weighted-Average Remai

Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)	Sep. 30, 2019
Leases [Abstract]
Weighted-average remaining lease term for operating leases	6 years
Weighted-average remaining lease term for finance leases	3 years
Weighted-average discount rate for operating leases	4.00%
Weighted-average discount rate for finance leases	4.00%

Leases - Cash Flow Disclosure (

Leases - Cash Flow Disclosure (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Leases [Abstract]
Operating cash flows from operating leases	$ 94
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 16

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Operating leases
2019	$ 32
2020	116
2021	99
2022	56
2023	35
Thereafter	80
Total lease payments	418
Less: Interest	43
Present value of lease liabilities	375
Finance leases
2019	6
2020	10
2021	9
2022	3
2023	1
Thereafter	0
Total lease payments	29
Less: Interest	1
Present value of lease liabilities	28
Total
2019	38	[1],[2]
2020	126	[1],[2]
2021	108	[1],[2]
2022	59	[1],[2]
2023	36	[1],[2]
Thereafter	80	[1],[2]
Total lease payments	447	[1],[2]
Less: Interest	44	[1],[2]
Present value of lease liabilities	403	[1],[2]
Contractual minimum lease payments for leases executed but not yet commenced	$ 350
Lease term for leases executed but not yet commenced	11 years
[1]	Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.
[2]	Total lease payments exclude approximately $350 million of contractual minimum lease payments for leases executed but not yet commenced. These leases will commence between years 2019 and 2020 with lease terms of approximately 11 years .

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measures - Financial Instruments (Details) £ in Millions, SFr in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2019EUR (€)	Sep. 30, 2019GBP (£)	Sep. 30, 2019CHF (SFr)	Dec. 31, 2018USD ($)	Dec. 31, 2018EUR (€)
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	$ 253				$ 132
Foreign currency contracts in liability position	139				492
Senior notes | September 2019 Senior Euro Notes
Derivative instruments, notional amount and fair value
Principal amount of unsecured senior notes | €		€ 1,400,000,000
Designated as hedging instrument | Net investment hedges | Senior notes
Derivative instruments, notional amount and fair value
Principal amount of unsecured senior notes | €		3,600,000,000				€ 3,600,000,000
Designated as hedging instrument | Net investment hedges | Senior notes | September 2019 Senior Euro Notes
Derivative instruments, notional amount and fair value
Principal amount of unsecured senior notes | €		1,400,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	$ 200				1,400
Duration of forward exchange contracts	18 months
Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold	6 months
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	$ 4				113
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Foreign currency contracts in liability position	0				0
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments		971,000,000	£ 204	SFr 62
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	69				0
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Foreign currency contracts in liability position	0				0
Designated as hedging instrument | Treasury rate lock agreements | Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	10,000
Designated as hedging instrument | Treasury rate lock agreements | Cash flow hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	123				0
Designated as hedging instrument | Treasury rate lock agreements | Cash flow hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Foreign currency contracts in liability position	35				0
Designated as hedging instrument | Interest rate contracts | Fair value hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	10,800				10,800
Designated as hedging instrument | Interest rate contracts | Fair value hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	0				0
Designated as hedging instrument | Interest rate contracts | Fair value hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Foreign currency contracts in liability position	8				0
Designated as hedging instrument | Interest rate contracts | Fair value hedges | Other assets
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	44				0
Designated as hedging instrument | Interest rate contracts | Fair value hedges | Other long-term liabilities
Derivative instruments, notional amount and fair value
Foreign currency contracts in liability position	59				466
Not designated as hedging instrument | Net investment hedges | Senior notes | Senior Euro Notes [Member]
Derivative instruments, notional amount and fair value
Principal amount of unsecured senior notes | €		€ 1,400,000,000
Not designated as hedging instrument | Foreign currency forward exchange contracts
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	6,200				8,600
Not designated as hedging instrument | Foreign currency forward exchange contracts | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	13				19
Not designated as hedging instrument | Foreign currency forward exchange contracts | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Foreign currency contracts in liability position	$ 37				$ 26

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Cost of products sold
Gain (loss) on derivatives
Foreign currency cash flow hedge gain expected to be reclassified during next 12 months	$ 50		$ 50
Interest expense, net
Gain (loss) on derivatives
Foreign currency cash flow hedge gain expected to be reclassified during next 12 months	3		3
Fair value hedges | Interest expense, net
Gain (loss) on derivatives
Debt designated as hedged item in fair value hedges gain (loss)	(78)	$ 63	(443)	$ 306
Foreign currency forward exchange contracts | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from derivative instruments designated as cash flow hedges recognized in other comprehensive income	3	1	8	122
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	59	0	69	0
Foreign currency forward exchange contracts | Not designated as hedges | Net foreign exchange loss
Gain (loss) on derivatives
Derivative gain (loss), net	(55)	22	(95)	91
Foreign currency forward exchange contracts | Cash flow hedges | Designated as hedging instrument | Cost of products sold
Gain (loss) on derivatives
Derivative gain (loss), net	42	(54)	119	(144)
Foreign currency forward exchange contracts | Net investment hedges | Designated as hedging instrument | Interest expense, net
Gain (loss) on derivatives
Derivative gain (loss), net	10	0	19	0
Interest rate swaps designated as fair value hedges | Fair value hedges | Designated as hedging instrument | Interest expense, net
Gain (loss) on derivatives
Derivative gain (loss), net	78	(63)	443	(306)
Treasury rate lock agreements | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from derivative instruments designated as cash flow hedges recognized in other comprehensive income	88	0	88	0
Senior notes | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	$ 152	$ (41)	$ 187	$ 95

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Assets
Foreign currency contracts	$ 253		$ 253		$ 132
Liabilities
Foreign currency contracts	139		139		492
Change in fair value recognized in net earnings			(2,653)	$ (432)
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Total liabilities	40,229		40,229		35,633
Significant other observable inputs (Level 2)
Liabilities
Total liabilities	28		28		3,729
Significant unobservable inputs (Level 3)
Liabilities
Total liabilities	0		0		0
Recurring
Assets
Cash and equivalents	10,648		10,648		7,289
Debt securities	2		2		1,536
Equity securities	62		62		4
Interest rate hedges	44		44
Total assets	10,965		10,965		9,529
Liabilities
Interest rate hedges	67		67		466
Contingent consideration	6,957		6,957		4,483
Total liabilities	7,096		7,096		4,975
Recurring | Foreign currency contracts
Assets
Foreign currency contracts	86		86		132
Liabilities
Foreign currency contracts	37		37		26
Recurring | Treasury rate lock agreements
Assets
Foreign currency contracts	123		123
Liabilities
Foreign currency contracts	35		35
Recurring | Time deposits
Assets
Time deposits					568
Recurring | Quoted prices in active markets for identical assets (Level 1)
Assets
Cash and equivalents	1,288		1,288		1,209
Debt securities	0		0		0
Equity securities	62		62		4
Interest rate hedges	0		0
Total assets	1,350		1,350		1,213
Liabilities
Interest rate hedges	0		0		0
Contingent consideration	0		0		0
Total liabilities	0		0		0
Recurring | Quoted prices in active markets for identical assets (Level 1) | Foreign currency contracts
Assets
Foreign currency contracts	0		0		0
Liabilities
Foreign currency contracts	0		0		0
Recurring | Quoted prices in active markets for identical assets (Level 1) | Treasury rate lock agreements
Assets
Foreign currency contracts	0		0
Liabilities
Foreign currency contracts	0		0
Recurring | Quoted prices in active markets for identical assets (Level 1) | Time deposits
Assets
Time deposits					0
Recurring | Significant other observable inputs (Level 2)
Assets
Cash and equivalents	9,360		9,360		6,080
Debt securities	2		2		1,536
Equity securities	0		0		0
Interest rate hedges	44		44
Total assets	9,615		9,615		8,316
Liabilities
Interest rate hedges	67		67		466
Contingent consideration	0		0		0
Total liabilities	139		139		492
Recurring | Significant other observable inputs (Level 2) | Foreign currency contracts
Assets
Foreign currency contracts	86		86		132
Liabilities
Foreign currency contracts	37		37		26
Recurring | Significant other observable inputs (Level 2) | Treasury rate lock agreements
Assets
Foreign currency contracts	123		123
Liabilities
Foreign currency contracts	35		35
Recurring | Significant other observable inputs (Level 2) | Time deposits
Assets
Time deposits					568
Recurring | Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	0		0		0
Debt securities	0		0		0
Equity securities	0		0		0
Interest rate hedges	0		0
Total assets	0		0		0
Liabilities
Interest rate hedges	0		0		0
Contingent consideration	6,957		6,957		4,483
Total liabilities	6,957		6,957		4,483
Recurring | Significant unobservable inputs (Level 3) | Foreign currency contracts
Assets
Foreign currency contracts	0		0		0
Liabilities
Foreign currency contracts	0		0		0
Recurring | Significant unobservable inputs (Level 3) | Treasury rate lock agreements
Assets
Foreign currency contracts	0		0
Liabilities
Foreign currency contracts	0		$ 0
Recurring | Significant unobservable inputs (Level 3) | Time deposits
Assets
Time deposits					$ 0
SKYRIZI
Liabilities
Change in fair value recognized in net earnings		$ (2,300)
Stemcentrx Inc.
Liabilities
Change in fair value recognized in net earnings	$ 91
Changes measurement | Change in assumed discount rate
Liabilities
Discount rate change			50.00%
Contingent consideration liability change			$ 270
Changes measurement | Change in assumed probability rate
Liabilities
Contingent consideration liability change			$ 140
Assumed probability rate change			5.00%

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Between The Fair Value Measurement Levels (Details)	9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)
Transfers of assets or liabilities between the fair value measurement levels
Transfer of assets from level 1 to level 2	$ 0
Transfer of assets from level 2 to level 1	0
Transfer of liabilities from level 1 to level 2	0
Transfer of liabilities from level 2 to level 1	0
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)
Beginning balance	4,483,000,000	$ 4,534,000,000
Change in fair value recognized in net earnings	(2,653,000,000)	(432,000,000)
Payments	(179,000,000)	(100,000,000)
Ending balance	$ 6,957,000,000	$ 4,866,000,000

Financial Instruments and Fai_7

Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Liabilities
Carrying amount of investments in equity securities that do not have readily determinable fair values	$ 67	$ 84
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Short-term borrowings		0
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	5,286	1,609
Long-term debt and finance lease obligations, excluding fair value hedges	34,943	34,024
Total liabilities	40,229	35,633
Significant other observable inputs (Level 2)
Liabilities
Short-term borrowings		3,693
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	7	8
Long-term debt and finance lease obligations, excluding fair value hedges	21	28
Total liabilities	28	3,729
Significant unobservable inputs (Level 3)
Liabilities
Short-term borrowings		0
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	0	0
Long-term debt and finance lease obligations, excluding fair value hedges	0	0
Total liabilities	0	0
Book value
Liabilities
Short-term borrowings		3,699
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	5,284	1,609
Long-term debt and finance lease obligations, excluding fair value hedges	33,141	35,468
Total liabilities	38,425	40,776
Approximate fair value
Liabilities
Short-term borrowings		3,693
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	5,293	1,617
Long-term debt and finance lease obligations, excluding fair value hedges	34,964	34,052
Total liabilities	$ 40,257	$ 39,362

Financial Instruments and Fai_8

Financial Instruments and Fair Value Measures - Available-for-sale Securities (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Available-for-sale Securities
Amortized cost		$ 1,546,000,000
Gross unrealized, Gains		1,000,000
Gross unrealized, Losses		(11,000,000)
Fair value		1,536,000,000
Other-than-temporary impairments	$ 0
Short-term investments
Available-for-sale Securities
Debt securities	$ 0	204,000,000
Asset backed securities
Available-for-sale Securities
Amortized cost		423,000,000
Gross unrealized, Gains		0
Gross unrealized, Losses		(2,000,000)
Fair value		421,000,000
Corporate debt securities
Available-for-sale Securities
Amortized cost		1,042,000,000
Gross unrealized, Gains		1,000,000
Gross unrealized, Losses		(9,000,000)
Fair value		1,034,000,000
Other debt securities
Available-for-sale Securities
Amortized cost		81,000,000
Gross unrealized, Gains		0
Gross unrealized, Losses		0
Fair value		$ 81,000,000

Financial Instruments and Fai_9

Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) - wholesaler	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Accounts receivable, net
Concentration of Risk
Number of principal customers	3
Accounts receivable, net | Geographic Risk
Concentration of Risk
Concentrations risk (as a percent)	68.00%	63.00%
Total revenues | HUMIRA
Concentration of Risk
Concentrations risk (as a percent)	58.00%	61.00%

Financial Instruments and Fa_10

Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) € in Millions, $ in Millions	1 Months Ended		9 Months Ended
	Oct. 31, 2019EUR (€)	Sep. 30, 2019USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019EUR (€)
Debt Instrument [Line Items]
Repayments of long-term debt | $			$ 5	$ 5,021
Senior notes | September 2019 Senior Euro Notes
Debt Instrument [Line Items]
Principal amount of unsecured senior notes					€ 1,400
Debt issuance costs incurred | $		$ 9	9
Debt discounts | $		$ 5	$ 5
Senior notes | Senior Euro Notes Due in 2027 at 0.750 Percent
Debt Instrument [Line Items]
Principal amount of unsecured senior notes					€ 750
Stated interest rate (as a percent)		0.75%	0.75%		0.75%
Senior notes | Senior Euro Notes Due in 2031 at 1.250 Percent
Debt Instrument [Line Items]
Principal amount of unsecured senior notes					€ 650
Stated interest rate (as a percent)		1.25%	1.25%		1.25%
Subsequent event | Senior notes | Senior Euro Notes 0.38 Percent Due 2019
Debt Instrument [Line Items]
Stated interest rate (as a percent)	0.38%
Repayments of long-term debt	€ 1,400
Minimum | Senior notes | September 2019 Senior Euro Notes
Debt Instrument [Line Items]
Senior note redemption period prior to maturity		1 month
Maximum | Senior notes | September 2019 Senior Euro Notes
Debt Instrument [Line Items]
Senior note redemption period prior to maturity		3 months

Financial Instruments and Fa_11

Financial Instruments and Fair Value Measures - Short-Term Borrowings (Details) - USD ($)	Jun. 25, 2019	Aug. 31, 2019	Mar. 31, 2019	May 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Jul. 12, 2019	Dec. 31, 2018
Short-Term Borrowings
Short-term borrowings					$ 0			$ 3,699,000,000
Repayments of other short-term borrowings					3,000,000,000	$ 0
Revolving credit facility
Short-Term Borrowings
Revolving credit facility maximum borrowing capacity		$ 4,000,000,000
Amount outstanding under company's credit facilities					0			0
Revolving credit facility term		5 years
Commercial paper
Short-Term Borrowings
Short-term borrowings					$ 0			$ 699,000,000
Weighted-average interest rate on commercial paper (as a percent)					2.50%	1.90%
Term loan facilities | May 2018 term loan credit agreement
Short-Term Borrowings
Repayments of other short-term borrowings			$ 3,000,000,000
Credit agreement term				364 days
Bridge credit agreement | June 2019 bridge credit agreement
Short-Term Borrowings
Credit agreement term	364 days
Revolving credit facility maximum borrowing capacity	$ 38,000,000,000						$ 32,000,000,000

Post-Employment Benefits (Detai

Post-Employment Benefits (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Defined benefit plans
Defined benefit and other post-employment plans
Service cost	$ 67	$ 70	$ 202	$ 214
Interest cost	64	57	194	171
Expected return on plan assets	(118)	(109)	(356)	(330)
Amortization of actuarial losses and prior service cost	27	38	82	114
Net periodic benefit cost	40	56	122	169
Other post-employment plans
Defined benefit and other post-employment plans
Service cost	6	7	19	20
Interest cost	6	6	21	18
Expected return on plan assets	0	0	0	0
Amortization of actuarial losses and prior service cost	1	0	1	1
Net periodic benefit cost	$ 13	$ 13	$ 41	$ 39

Equity - Stock-Based Compensati

Equity - Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	$ 75	$ 75	$ 351	$ 351
Tax benefit	15	13	64	61
After-tax compensation expense	60	62	287	290
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	4	7	24	23
Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	31	32	136	139
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	$ 40	$ 36	$ 191	$ 189

Equity - Stock Options (Details

Equity - Stock Options (Details) - Stock Options $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award
Stock options granted (in shares) | shares	1
Weighted-average grant-date fair value of the stock options granted (in dollars per share) | $ / shares	$ 12.54
Unrecognized compensation cost | $	$ 7
Period for recognition of unrecognized compensation cost	2 years

Equity - RSUs and Performance S

Equity - RSUs and Performance Shares (Details) - RSUs and Performance Shares $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award
Shares granted (in shares) | shares	5.5
Fair market value of awards vested (in dollars per share) | $ / shares	$ 78.55
Unrecognized compensation cost | $	$ 365
Period for recognition of unrecognized compensation cost	2 years

Equity - Cash Dividends (Detail

Equity - Cash Dividends (Details) - $ / shares	Nov. 01, 2019	Sep. 06, 2019	Jun. 20, 2019	Feb. 21, 2019	Nov. 02, 2018	Sep. 07, 2018	Jun. 14, 2018	Feb. 15, 2018
Dividends Payable
Cash dividends declared per common share (in dollars per share)		$ 1.07	$ 1.07	$ 1.07	$ 1.07	$ 0.96	$ 0.96	$ 0.96
Subsequent event
Dividends Payable
Cash dividends declared per common share (in dollars per share)	$ 1.18

Equity - Stock Repurchase Progr

Equity - Stock Repurchase Program (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Equity, Class of Treasury Stock
Payment for shares repurchased	$ 3	$ 1,009	$ 425	$ 9,956
Remaining share repurchase authorization amount	$ 4,000		$ 4,000
December 2018 Stock Repurchase Authorization
Equity, Class of Treasury Stock
Shares repurchased (in shares)			4
Payment for shares repurchased			$ 300
February 2017 Stock Repurchase Program
Equity, Class of Treasury Stock
Shares repurchased (in shares)				94
Payment for shares repurchased				$ 9,800

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
AOCI Attributable to Parent, Net of Tax
Beginning balance	$ (8,566)	$ (3,375)	$ (8,446)	$ 5,097
Other comprehensive income (loss)	(37)	80	(48)	168
Ending balance	(8,226)	(2,921)	(8,226)	(2,921)
Accumulated other comprehensive loss
AOCI Attributable to Parent, Net of Tax
Beginning balance	(2,491)	(2,639)	(2,480)	(2,727)
Other comprehensive income (loss) before reclassifications			12	(66)
Net losses (gains) reclassified from accumulated other comprehensive loss			(60)	234
Other comprehensive income (loss)	(37)	80	(48)	168
Ending balance	(2,528)	(2,559)	(2,528)	(2,559)
Foreign currency translation adjustments
AOCI Attributable to Parent, Net of Tax
Beginning balance			(830)	(439)
Other comprehensive income (loss) before reclassifications			(288)	(250)
Net losses (gains) reclassified from accumulated other comprehensive loss			0	0
Other comprehensive income (loss)			(288)	(250)
Ending balance	(1,118)	(689)	(1,118)	(689)
Net investment hedging activities
AOCI Attributable to Parent, Net of Tax
Beginning balance			(65)	(203)
Other comprehensive income (loss) before reclassifications			199	73
Net losses (gains) reclassified from accumulated other comprehensive loss			(15)	0
Other comprehensive income (loss)			184	73
Ending balance	119	(130)	119	(130)
Pension and post-employment benefits
AOCI Attributable to Parent, Net of Tax
Beginning balance			(1,722)	(1,919)
Other comprehensive income (loss) before reclassifications			12	7
Net losses (gains) reclassified from accumulated other comprehensive loss			66	92
Other comprehensive income (loss)			78	99
Ending balance	(1,644)	(1,820)	(1,644)	(1,820)
Marketable security activities
AOCI Attributable to Parent, Net of Tax
Beginning balance			(10)	0
Other comprehensive income (loss) before reclassifications			12	(6)
Net losses (gains) reclassified from accumulated other comprehensive loss			(2)	4
Other comprehensive income (loss)			10	(2)
Ending balance	0	(2)	0	(2)
Cash flow hedging activities
AOCI Attributable to Parent, Net of Tax
Beginning balance			147	(166)
Other comprehensive income (loss) before reclassifications			77	110
Net losses (gains) reclassified from accumulated other comprehensive loss			(109)	138
Other comprehensive income (loss)			(32)	248
Ending balance	$ 115	$ 82	$ 115	$ 82

Equity - Amounts Reclassified O

Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Significant amounts reclassified out of each component of AOCI
Losses (gains) on foreign currency forward exchange contracts		$ 1,920	$ 1,835	$ 5,433	$ 5,696
Gains on derivative amount excluded from effectiveness testing		420	302	1,054	825
Tax expense (benefit)		117	14	271	57
Total reclassifications, net of tax		(1,884)	(2,747)	(5,081)	(7,513)
Pension and post-employment benefits
Significant amounts reclassified out of each component of AOCI
Amortization of actuarial losses and other	[1]	28	38	83	115
Tax benefit		(5)	(8)	(17)	(23)
Total reclassifications, net of tax		23	30	66	92
Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Losses (gains) on foreign currency forward exchange contracts	[2]	(42)	54	(119)	144
Tax expense (benefit)		3	0	10	(6)
Total reclassifications, net of tax		(39)	54	(109)	138
Net investment hedging activity | Reclassification out of accumulated other comprehensive loss | Net investment hedging activities
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing	[3]	(10)	0	(19)	0
Tax expense (benefit)		2	0	4	0
Total reclassifications, net of tax		$ (8)	$ 0	$ (15)	$ 0
[1]	Amounts are included in the computation of net periodic benefit cost (see Note 10 ).
[2]	Amounts are included in cost of products sold (see Note 9 ).
[3]	Amounts are included in interest expense, net (see Note 9 ).

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Effective tax rate	6.00%	1.00%	5.00%	1.00%
U.S. statutory tax rate			21.00%	21.00%
Potential change in unrecognized tax benefits	$ 193		$ 193

Legal Proceedings and Conting_2

Legal Proceedings and Contingencies (Details)	1 Months Ended						9 Months Ended
	Sep. 30, 2019USD ($)claimdirect_purchaser	Jun. 30, 2018USD ($)	Mar. 31, 2017	Jun. 30, 2016investment_fund	Nov. 30, 2014individual	Sep. 30, 2014company	Sep. 30, 2019USD ($)claim	Sep. 30, 2019USD ($)claimdirect_purchaser	Sep. 30, 2019USD ($)claimcompany	Sep. 30, 2019USD ($)claimlawsuit	Sep. 30, 2019USD ($)claimclass_action	Sep. 30, 2019USD ($)claimend_payor_purchaser	Dec. 31, 2018USD ($)
Legal Proceedings and Contingencies
Recorded accrual balance for litigation | $	$ 325,000,000						$ 325,000,000	$ 325,000,000	$ 325,000,000	$ 325,000,000	$ 325,000,000	$ 325,000,000	$ 350,000,000
Number of individual putative class action lawsuit | individual					5
Percentage of claims subject to settlement agreements							90.00%
Depakote
Legal Proceedings and Contingencies
Number of claims pending | claim	150						150	150	150	150	150	150
AndroGel Antitrust Litigation
Legal Proceedings and Contingencies
Recorded accrual balance for litigation | $	$ 0						$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Number of generic companies with whom certain litigation related agreements were entered into | company						2			3
Number of healthcare benefit providers acting as plaintiff in lawsuit | direct_purchaser	2
AndroGel Antitrust Litigation | Disgorgement remedy
Legal Proceedings and Contingencies
Damages awarded against company | $		$ 448,000,000
Niaspan
Legal Proceedings and Contingencies
Number of healthcare benefit providers acting as plaintiff in lawsuit								1				1
Number of individual plaintiff lawsuits | lawsuit										4
Number of purported class actions | class_action											2
Elliott Associates, L.P.
Legal Proceedings and Contingencies
Number of parties to lawsuit (in investment funds) | investment_fund				5
Testosterone Replacement Therapy Products Liability Litigation
Legal Proceedings and Contingencies
Numbers of claims consolidated for pre-trial purposes | claim	3,900						3,900	3,900	3,900	3,900	3,900	3,900
Number of claims pending | claim	200						200	200	200	200	200	200
Novartis Vaccines and Diagnostics Inc and Grifols Worldwide Operations Ltd [Member]
Legal Proceedings and Contingencies
HCV-related patents			11

Segment Information - Additiona

Segment Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2019segment
Segment Reporting [Abstract]
Number of operating segments	1

Segment Information - Disaggreg

Segment Information - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation of Revenue
Total net revenues	$ 8,479	$ 8,236	$ 24,562	$ 24,448
All other
Disaggregation of Revenue
Net revenues	83	22	438	250
Immunology | HUMIRA
Disaggregation of Revenue
Net revenues	4,936	5,124	14,252	15,018
Immunology | HUMIRA | United States
Disaggregation of Revenue
Net revenues	3,887	3,546	10,895	10,070
Immunology | HUMIRA | International
Disaggregation of Revenue
Net revenues	1,049	1,578	3,357	4,948
Immunology | SKYRIZI
Disaggregation of Revenue
Net revenues	91	0	139	0
Immunology | SKYRIZI | United States
Disaggregation of Revenue
Net revenues	76	0	118	0
Immunology | SKYRIZI | International
Disaggregation of Revenue
Net revenues	15	0	21	0
Immunology | RINVOQ | United States
Disaggregation of Revenue
Net revenues	14	0	14	0
Hematologic Oncology | IMBRUVICA
Disaggregation of Revenue
Net revenues	1,257	972	3,378	2,584
Hematologic Oncology | IMBRUVICA | United States
Disaggregation of Revenue
Net revenues	1,042	812	2,757	2,129
Hematologic Oncology | IMBRUVICA | International
Disaggregation of Revenue
Collaboration revenues	215	160	621	455
Hematologic Oncology | VENCLEXTA
Disaggregation of Revenue
Net revenues	221	96	541	220
Hematologic Oncology | VENCLEXTA | United States
Disaggregation of Revenue
Net revenues	142	69	364	157
Hematologic Oncology | VENCLEXTA | International
Disaggregation of Revenue
Net revenues	79	27	177	63
HCV | MAVYRET
Disaggregation of Revenue
Net revenues	695	839	2,265	2,619
HCV | MAVYRET | United States
Disaggregation of Revenue
Net revenues	368	444	1,167	1,206
HCV | MAVYRET | International
Disaggregation of Revenue
Net revenues	327	395	1,098	1,413
HCV | VIEKIRA
Disaggregation of Revenue
Net revenues	3	23	32	135
HCV | VIEKIRA | United States
Disaggregation of Revenue
Net revenues	0	0	0	3
HCV | VIEKIRA | International
Disaggregation of Revenue
Net revenues	3	23	32	132
Other Key Products | Creon | United States
Disaggregation of Revenue
Net revenues	265	239	749	667
Other Key Products | Lupron
Disaggregation of Revenue
Net revenues	230	214	668	656
Other Key Products | Lupron | United States
Disaggregation of Revenue
Net revenues	187	173	546	530
Other Key Products | Lupron | International
Disaggregation of Revenue
Net revenues	43	41	122	126
Other Key Products | Synthroid | United States
Disaggregation of Revenue
Net revenues	197	192	582	567
Other Key Products | Synagis | International
Disaggregation of Revenue
Net revenues	132	97	457	462
Other Key Products | Duodopa
Disaggregation of Revenue
Net revenues	117	106	343	317
Other Key Products | Duodopa | United States
Disaggregation of Revenue
Net revenues	26	19	72	57
Other Key Products | Duodopa | International
Disaggregation of Revenue
Net revenues	91	87	271	260
Other Key Products | Sevoflurane
Disaggregation of Revenue
Net revenues	84	86	267	305
Other Key Products | Sevoflurane | United States
Disaggregation of Revenue
Net revenues	18	18	53	54
Other Key Products | Sevoflurane | International
Disaggregation of Revenue
Net revenues	66	68	214	251
Other Key Products | Kaletra
Disaggregation of Revenue
Net revenues	74	88	229	252
Other Key Products | Kaletra | United States
Disaggregation of Revenue
Net revenues	7	16	30	42
Other Key Products | Kaletra | International
Disaggregation of Revenue
Net revenues	67	72	199	210
Other Key Products | AndroGel | United States
Disaggregation of Revenue
Net revenues	53	135	149	393
Other Key Products | ORILISSA
Disaggregation of Revenue
Net revenues	27	3	59	3
Other Key Products | ORILISSA | United States
Disaggregation of Revenue
Net revenues	27	3	58	3
Other Key Products | ORILISSA | International
Disaggregation of Revenue
Net revenues	$ 0	$ 0	$ 1	$ 0

Uncategorized Items - abbv-2019

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (1,733,000,000)
Common Stock [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(1,733,000,000)
Treasury Stock [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 0